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Abstract 
Transforming growth factor beta-1 (TGF-β1) is a cytokine involved in immune modulation 
and tissue regeneration and has a polymorphic TGFB1 promoter. African-specific single 
nucleotide polymorphisms (SNPs) have been identified in the TGFB1 promoter and they occur 
at higher frequencies in South Africans with African-genetic ancestry (≈17%) compared with 
West and East African genomes (<5%). However, the functional significance of these SNPs 
has only been partially explored. In this study it was hypothesized that higher frequencies of 
immune-mediated disease complications in South Africans, such as HIV-associated 
nephropathy (HIVAN), may be influenced by functional genetic variations in TGFB1. To 
address this, the African-specific TGFB1 haplotypes containing singular, or combinations of, -
1287 G>A (rs11466314), -1154 C>T (rs35318502), -387 C>T (rs11466316) and -14 G>A 
(rs9282871) were investigated for their effect on TGFB1 promoter activity. Briefly, an 
extended TGFB1 regulatory region driving a luciferase reporter was used as a template to 
generate six TGFB1 promoter haplotypes (referred to as H-1 through H-6 in this thesis) by 
site-directed mutagenesis and luciferase activity was used to measure promoter activity. The 
functional TGFB1 -1347 C>T variant was also investigated (H-5 and H-6 containing -1347 C 
and T alleles, respectively) because all four of the African variants more frequently co-
occurred with the previously reported “lower expressing” TGFB1 -1347 C variant (H-1 
through H-4). Transient transfection of the TGFB1 promoter reporter constructs in two renal 
cell lines (RCC4+VHL and Caki-2) showed no difference between -1347 C (H-5) and T (H-6) 
basal promoter activity. Having at least one African variant resulted in ~5-fold loss of basal 
TGFB1 promoter activity in renal cells when compared to the most common haplotype (H-5) 
(p<0.05). The repressive effect is mainly attributed to the -387 T variant (H-1) as the addition 
of other African variants on this haplotype showed no additional TGFB1 promoter repression. 
The repressive effect of the TGFB1 -387 T variant was maintained even after in-vitro 
treatment of transfected renal cells with recombinant human TGF-β1 (rhTGF-β1). 
To determine whether the African-specific TGFB1 promoter haplotypes (H-AFR), containing 
TGFB1 -387 T and tested in luciferase assays, also impact on endogenous TGF-β1 protein 
levels, western blot analysis was performed on human dermal fibroblasts from patients who 
had been genotyped. Similar to the promoter studies, basal TGF-β1 protein levels in cells with 
the H-AFR were ~47% lower compared to cells without (p=0.04) and no difference was seen 
in response to hrTGF-β1. Interestingly, when western blots were screened for phosphorylated 
Smad3 (pSmad3) protein levels, as an indicator of the activated TGF-β1 canonical pathway, 
similar pSmad3 levels were observed under basal and hrTGF-β1 stimulated conditions for all 
haplotypes (p>0.05).  
The possible interaction of HIV tat on the African TGFB1 promoter variants was also 
assessed. Luciferase activity was measured after co-transfecting renal RCC4+VHL and 
HT1080 fibroblast cells with a HIV Tat expression vector and the H-6, H-5 and H-AFR 
promoter luciferase constructs. Results showed that the promoter activity for all TGFB1 
haplotypes was upregulated in the renal cells (≥1.6-fold; p<0.001). The same result was, 
however, only observed for TGFB1 haplotypes H-5 and H-AFR in the fibroblast cells (≥1.4-
9 
fold; p<0.01). This is interesting because no difference was seen between TGFB1 H-5 and H-6 
basal promoter activity. 
To investigate whether histopathological severity of HIVAN correlated with TGF-β1 staining 
patterns, immunohistochemistry was performed on 20 renal biopsies from patients with 
HIVAN. A semi-quantitative “histo” score (H-score) was calculated by multiplying the 
percentage of positive cells with the intensity of the stain before comparing the scores with 
control biopsies (HIV-negative, n=3 and HIV-positive without HIVAN, n=3 biopsies). 
Compared to the HIV-positive controls the kidney tubules of HIVAN biopsies had higher H-
scores. Strikingly, the interstitium of HIVAN samples stained much more prominently (17/18) 
than both control groups suggesting that TGF-β1 staining in the renal interstitium appear to be 
specific for HIVAN.  
In conclusion this study shows that the African-specific haplotypes effect basal TGFB1 
promoter activity and TGF-β1 protein levels. However, they do not seem to affect the 
cytoplasmic TGF-β1/pSmad3 protein levels in response to rhTGF-β1 autocrine stimulation. 
Immunohistochemistry results suggest that TGF-β1 pathway may be prominently dysregulated 
in the renal interstitium of HIVAN cases. 
1. Introduction
1.1 TGF-β1 as a cytokine 
TGF-β1 plays an important role in immune signalling, growth and developmental processes as 
well as contributing to the pathogenesis of fibrotic disease in many tissues including the 
kidney (Olson et al. 1986; Leask & Abraham 2004). TGF-β1 protein levels are highly 
regulated, requiring activation from the inactive precursor present in the extracellular matrix in 
order to become active latent complexes (Nunes et al. 1997). As a latent complex TGF-β1 can 
interact with many cell types, such as muscle and kidney cells, by initiating signalling across 
the plasma membrane into the cell (Heldin et al. 1997). The signalling happens through 
induced heteromeric complexes of type I and type II receptors with serine/threonine kinase 
activity (Wrana et al. 1994).  
TGF-β1 is usually increased by an inflammatory response such as tissue injury. In response to 
an increase in TGF-β1 levels, myoblasts and fibroblasts are induced to express more TGF-β1 
and initiate the production of fibrogenic proteins which convert them to a myofibroblast 
phenotype (Li et al. 2004; Böttinger 2007). Myofibroblasts are key cellular components in 
fibrotic lesions and cause the accumulation of fibrogenic extracellular matrix which result in 
impaired function (Lehto et al. 1986; Montesano & Orci 1988; Leask & Abraham 2004). TGF-
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β1 activates a host of fibrotic cytokines that help in the remodelling and repair of damaged 
tissue, but when overexpressed may lead to unfavourable scarring and altered healing of 
kidney cells (Kovacs & DiPietro 1994; Epstein et al. 1994; Wynn 2010). It is pertinent to note 
that TGF-β1 has been shown to have both pro-fibrotic as well as anti-inflammatory roles often 
occurring in different cellular contexts. Interestingly, depending on the duration of renal 
injury, TGF-β1 signalling is able to switch from an anti-inflammatory role in acute kidney 
damage to a pro-fibrotic role in chronic kidney damage. This dual functionality suggests that 
TGF-β1 levels and functional effects are both complex and tightly regulated in a renal context 
(Roberts et al. 1986; Border & Noble 1994; Wang et al. 2005).  
1.2 TGF-β1 signalling 
Upon ligand-induced activation of TGF-β1 receptors the receptor-complexes are able to 
signal to the cell nucleus via the Smad (signalling mother against decapentaplegic peptide) 
family of proteins (Heldin et al. 1997). Smad proteins act as messengers of gene regulation at 
the transcript level (Kim et al. 1989; Heldin et al. 1997; Shi & Massague 2003). Figure 1.1 
illustrates the binding of TGF-β1 to the serine-threonine kinase receptors (TβRI and TβRII) 
on the cell surface. The TβRI-kinase then phosphorylates the receptor-regulated Smads (R-
Smads) such as Smad2 and Smad3 which then forms a transcriptional complex with a 
common-partner Smad (Co-Smads) such as Smad4 (Lan 2011). The R-Smad/Co-Smad 
complex then enters the nucleus, where it binds to promoters and transcription co-factors in 
order to activate the transcription of genes (Leask & Abraham 2004; Lan 2011).  The R-
Smads (Smad2/3) and Co-Smad (Smad4) complexes are regulated by the inhibitory Smads 
(I-Smads) such as Smad7 (Figure 1.1) (Lan 2011).  
TGF-β1 is expressed in the proximal renal tubular epithelial cells (referred to as renal tubular 
epithelial cells in this thesis) located in the renal cortex (Figure 1.2). The renal cortex is the 
outer layer of the kidney and the medulla the inner layer; the nephron is a tube-like structure 
spanning both of these layers (Figure 1.2). The nephron is the functional unit of the kidney 
where ultrafiltration occurs; podocytes, glomeruli and renal tubules are located in this area. In 
the kidney TGF-β1 has complex pro-fibrotic and anti-inflammatory roles and is able to switch 
between these two roles depending on the environmental stress as well as the mechanism by 
which the Smad pathway is activated or inhibited (TGF-β1-dependent and -independent 
signalling). In the context of kidney disease it has been shown that the downstream canonical 
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Smad2/3 pathway can be activated by TGF-β1 and mitogen-activated protein kinase (MAPK) 
signalling (also known as the ERK/p38 MAP kinase-dependent mechanism) (Wang et al. 













Figure 1.1: Schematic showing TGF-β1 activated Smad pathway and how this signalling 
pathway regulates gene expression. The involvement of NF-!β and the ERK/p38/MAP kinase 
pathways are also shown together with the inhibitory Smad7. TβR-I and TβR-II refer to type 1 
and type 2 receptor and ‘p’ indicates phosphorylation. 
 
Chronic kidney injury and the subsequent increase in TGF-β1 protein levels induce epithelial 
to mesenchymal transition (EMT). During EMT the TGF-β/Smads (Smad2 and Smad3) and 
BMP/Smads (Smad1, Smad5 and Smad8) counter regulate each other in order to maintain 
balance between the two pathways whereby one promotes inflammation and fibrosis and the 
other inhibits those effects, respectively (Bonniaud et al. 2005; Wang et al. 2005; Lan 2011). 
Previously, Smad2 knockout studies in a mouse model showed that Smad2 not only enhances 
the phosphorylation of Smad3 and its binding to various promoters that play a role in collagen 
matrix production, such as the ColA1 promoter, but may also be able to competitively inhibit 
the phosphorylation of Smad3 in response to TGF-β1 (Bonniaud et al. 2005; Lan 2012). The 
interaction between Smad2/3 and Smad4 (formation of the transcription complex) can also 
have an effect on the nuclear translocation of phosphorylated Smad3 and its subsequent 
binding to target genes. Smad7, an inhibitor of the Smad2/3 complex, can promote nuclear 
factor kappa-light-chain-enhancer of activated B cells–dependent (NF-!β) renal inflammation 
(Lan 2012). NF-!β is a protein complex that controls the transcription of genes including 
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cytokines and is activated during kidney disease where it regulates renal inflammation (Lan 
2011; Lan 2012). It has been demonstrated that TGF-β1 can induce Smad7 mRNA expression 
during chronic kidney injury which leads to the activation of Smurf proteins (E3 ubiquitin-
protein ligase) which in turn leads to Smad7 degradation and enhanced activation of Smad2/3 
and NF-!β-dependent inflammatory pathways (Lan 2011). This highlights the complexity of 
TGF-β1 signalling during kidney disease where inhibitors, such as Smad7, can now also 
activate the Smad2/3 pathway.  
Figure 1.2: Schematic showing the anatomy of the kidney. The renal cortex contains the 
tubular epithelial cells where TGF-β1 is expressed during acute and chronic kidney injury. 
Image sourced form http://antranik.org/the-urinary-system-kidneys/ 
Renal cells, and others, are able to respond to autocrine and paracrine TGF-β1 signalling 
(Bódi et al. 1997; Nunes et al. 1997; Böttinger 2007). Auto-induction of TGF-β1 in the kidney 
can lead to prolonged fibrosis through the MAP kinase pathway and is also responsible for 
increased production of the extracellular matrix (ECM) through activation of connective tissue 
13 
growth factors and collagen proteins (Roberts et al. 1986; Bonniaud et al. 2005; Zhang et al. 
2006). When there is chronic kidney injury, such as HIV-infection, prolonged TGF-β1 
signalling occurs which can lead to severe fibrosis and scaring. 
1.3 TGFB1 transcriptional control and promoter polymorphisms 
The TGFB1 gene has two major start sites regulated by a complex and extensive promoter 
which controls TGFB1 mRNA levels (Kim et al. 1989). Comprehensive analysis of the 
different regulatory elements, -2665bp upstream of the ATG translation start site, has revealed 
various functional promoter regions (shown in Figure 1.3) that act as either enhancers or 
negative regulators of gene transcription (Kim et al. 1989). It is known that mutations in the 5’ 
or 3’ regulatory regions of cytokines can have a significant effect on transcription and protein 
expression, as they have the potential to influence mRNA splicing, mRNA stability (3’UTR) 
and levels of gene expression (5’UTR) (Bidwell et al. 1999). The TGFB1 promoter (5’UTR) is 
highly polymorphic and many of these single nucleotide polymorphisms (SNPs) have been 
shown to be functional as they alter binding affinity of  nuclear factors/transcription factors in 
electrophoretic mobility shift assays (EMSA) and influence reporter gene expression in 
promoter studies (Shah, Rahaman, et al. 2006; Healy et al. 2009; Mohy & Fouad 2014). Since 
TGFB1 is a key player in signalling networks related to immune regulation and tissue injury, 
functional SNPs which alter the level of this cytokine, could understandably have detrimental 
outcomes to tissue healing responses (Lehto et al. 1986; Roberts et al. 1986). Indeed, many 
studies have implicated TGFB1 genetic variants in a variety of disease complications though 
few have interrogated African-specific TGFB1 SNPs specifically (Shah, Rahaman, et al. 2006; 
Healy et al. 2009; Nel et al. 2015).  
Nel et al. (2015) previously studied a tissue specific complication observed in autoimmune 
myasthenia gravis using an extended TGFB1 promoter construct (Figure 1.3A), focusing on 
the effect of the African-specific TGFB1 -387 C>T variant and found that it associated with 
the development of the complication. Their study showed that this SNP is functional and 
significantly represses TGFB1 promoter activity in reporter gene assays and patient specific 
fibroblasts with -387 T were shown to have significantly lower TGF-β1 protein levels than 
those with the -387 C allele (3). Therefore, there is evidence that the TGFB1 -387 C>T variant 
may impact TGFB1 expression levels and its effect may be the same in cells of kidney origin. 
Nel et al. (2015) also investigated the functionality of the African-specific TGFB1 -14 G>A 
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SNP in fibroblast and myoblast cells and found it not to be functional. The functionality of the 
two other African-specific SNPs, -1287 G>A and -1154 C>T, have not been investigated 
using the extended TGFB1 promoter and were therefore included in this study. Nel et al. 
(2015) also investigated the TGFB1 -1347 C>T SNP site, also known as the -509 C>T, and 
found that the T allele increased TGFB1 promoter activity in fibroblast and myoblast cells. 
Two shorter TGFB1 promoter constructs have also been used in previous studies to investigate 
the functionality of the TGFB1 -1347 C>T (-509 C>T), -1287 G>A and -1154 C>T variants, 
but they lacked some of the regulatory regions and the functional -387 C>T variant (Figure 
1.3B and C). 
Figure 1.3: Schematic of the human extended TGFB1 5’UTR cloned into a luciferase reporter 
construct with 10 polymorphic sites, four of which are African-specific. B and C are two 
shorter/incomplete promoter constructs previously used in functional studies. Figure sourced 
from Nel et al. (2015). Regulatory regions and polymorphisms indicated relative to the ATG 
translation start site. 
A brief synopsis of TGFB1 and renal complications 
The kidney is particularly susceptible to fibrotic disease as the production of extracellular 
matrix; appearance of myofibroblasts and inflammatory cells are triggered in response to renal 
insults (Montesano & Orci 1988; Böttinger 2007). The role of TGF-β1 in the pathogenesis of 
renal fibrosis is well established and it is of interest to note that there is research to suggest 





complications such as hypertensive kidney disease and HIV-associated nephropathy (HIVAN) 
(Suthanthiran et al. 1998; Eiser 2010). Several conditions related to TGF-β1 appear to be more 
common in African-American individuals, suggesting that there is a genetic component that 
contributes to the development of adverse disease complications upon immune insult. In 
addition, nephrologists in South Africa (SA) have reported that the incidence of HIVAN 
appears to be higher in individuals with African-genetic ancestry (Wearne 2012; Kasembeli 
2015). The fact that TGF-β1 signalling is so critical in renal homeostasis leads one to 
speculate that TGFB1 promoter variation may also be involved in modulating adverse kidney 
disease outcomes in Africans with HIV.  
Briefly, HIVAN is characterised by histopathological features such as collapsing glomeruli, 
interstitial inflammation, interstitial fibrosis and tubular abnormalities (microcyst formation) 
within the renal cortex. These pathological features can  reduce the excretory renal function 
and lead to end-stage renal failure (Liu 2006; Wyatt & Klotman 2009; Medapalli et al. 2011). 
TGF-β1 induces fibroblast proliferation and the secretion of extracellular matrix components 
in the case of acute injury or chronic/persistent kidney injury (August et al. 2009; Wynn 
2010). In acute injury, the epithelial cells nearest the site of injury will produce low levels of 
TGF-β1 which stimulate fibroblast proliferation but this modest increase in TGF-β1 levels 
does not perturb fibroblasts from their resting state (Figure 1.4). However, the epithelial cells 
will enter the cell cycle and start to proliferate and will repair the site of injury (Figure 1.4) 
(Yang et al. 2010). When there is chronic kidney injury the majority of epithelial cells will 
arrest between G2 and M phases of the cell cycle and stimulate increased production of TGF-
β1, in an autocrine/paracrine fashion (Overall et al. 1989; Wynn 2010). The increase in TGF-
β1 simultaneously results in a decrease of proteins such as matrix metalloproteinases, which 
degrade the extracellular matrix (ECM), and directs the activated fibroblasts to differentiate 
into myofibroblasts (referred to as EMT) (Wynn 2010). These myofibroblasts will then 
activate the production of extracellular matrix proteins, such as collagen I, which ultimately 
lead to a pathogenic fibrotic response instead of normal kidney repair (Figure 1.4) (Liu 2006; 
Lan 2011). 
Increased levels of TGF-β1 in the kidney have been associated with HIVAN where fibrosis is 
activated by changes in cytokine release during HIV infection (Abbott et al. 2001; X. Cheng et 
al. 2013). Studies on African-American patients with HIVAN have shown differential 
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expression of TGFB1 in their kidneys compared to Caucasians (Abbott et al. 2001; Eiser 
2010). Thus, this study hypothesised that excessive upregulation of the TGF-β1 signalling 
pathway may be implicated in Africans who develop HIVAN and in turn may implicate 
functional African-specific TGFB1 promoter polymorphisms. Therefore, this study  
investigated the African TGFB1 promoter SNPs (-1287 G>A, -1154 C>T , -387 C>T and -14 
G>A) using an extended TGFB1 promoter, which has not been previously used to examine
functionality of these variants in kidney cells.
Figure 1.4: Schematic showing TGF-β1 signalling in the kidney during A) acute and B) 
chronic kidney injury. Figure adapted from Wynn et al. (2010). 
HIVAN risk alleles in the Apoloprotein-1 gene 
A region on chromosome 22q12 encoding Apoliprotein-1 (APOL1) has been associated with 
increased risk of HIVAN in patients with African-ancestry (Genovese et al. 2010). Previous 
genome wide association studies (GWAS) revealed that the increased risk is due to three 
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al. 2011; Tayo et al. 2013; Kasembeli et al. 2015). Two tightly linked G1 risk alleles, termed 
G1S342G and G1I384M, and one 6 base pair deletion termed G2 (G2"6) have been identified as 
the HIVAN risk alleles (Genovese et al. 2010; Kasembeli et al. 2015). The G1 and G2 alleles 
are mutually exclusive, never occurring on the same allele. The G1 risk variants have been 
identified as the main contributors to increased susceptibility of HIVAN in patients with 
African-ancestry (Kasembeli et al. 2015). Kasembeli et al. (2015) showed that the G1GM
(containing both G1 risk alleles but not the G2 allele) haplotype is the most common 
occurring haplotype in a Johannesburg HIVAN group with a haplotype frequency of 0.53 
compared to a haplotype frequency of 0.06 in population controls (Kasembeli et al. 2015). 
Therefore this study included the APOL1 risk alleles in the genotyping of a Cape Town 
HIVAN sample with African-ancestry comprising 20 individuals. In this work the minor 
allele frequencies and haplotype frequencies of the APOL1 risk alleles will be determined for 
a Cape Town HIVAN group.  
Apoloprotein-1 (APOL1) can be expressed extracellularly, where it provides resistance 
against trypanosomes, or intracellularly where it functions as a crucial component in the 
human host defence as well as cellular homeostasis (Hu et al. 2012). Intracellular expression 
of APOL1 in renal tubular epithelial cells and podocytes can induce low levels of autophagy 
which act to maintain cellular homeostasis in the kidney (Hu et al. 2012). Variants in the 
APOL1 gene can lead to an upregulation of APOL1 in renal tubular epithelial cells which in 
turn can induce apoptotic or proliferative changes in these cells (Hu et al. 2012).  
microRNAs in HIVAN 
In addition to variants in the 5’UTR there are also mechanisms in the 3’UTR that can 
influence TGF-β1 levels in the kidney. MicroRNA-200 (miRNA-200) has recently been 
shown to play a role in the pathogenesis of HIVAN (Kato et al. 2011; K. Cheng et al. 2013). 
Its downregulation in podocytes leads to the collapse of the glomerulus, more commonly 
known as collapsing focal segmental glomerulosclerosis (FSGS), and is also able to induce 
EMT of the tubular epithelial cells (K. Cheng et al. 2013). 
HIV Tat increases TGFB1 mRNA expression 
HIV-1-trans-activating (Tat) protein is encoded by the Tat gene and functions as an early 
RNA binding protein enhancing the efficiency of viral transcription (Lotz et al. 1994). HIV 
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Tat has been predicted to have a trans-activation response element (TAR-like) binding 
sequence on the TGFB1 regulatory region, but seems unlikely to be able to bind due to the 
absence of a stem-loop structure (Thatikunta et al. 1997). Therefore it is speculated that the 
enhanced TGFB1 mRNA expression seen in response to HIV Tat dosage may be due to the 
induction or promoter binding proteins. However, functional studies on the effect of HIV Tat 
on the TGFB1 promoter activity are lacking. Yamamoto et al. 1999 showed that there was an 
increase in TGF-β1 staining levels in renal biopsies from HIV-positive patients with African-
ancestry when compared with HIV-positive normal and HIV-negative kidneys, identifying 
TGF-β1 as a mediating factor in the pathogenesis of HIVAN and end-stage renal disease 
(Yamamoto et al. 1999). In order to investigate whether HIV Tat has an effect on the TGFB1 
regulatory region, and specifically the African-specific variants, this study set out to perform 
luciferase reporter assays using co-transfections of the TGFB1 African haplotypes as well as 
an HIV Tat expression vector (provided by Dr. Mowla from the University of Cape Town) in 
renal and fibroblast cells (representing the renal tubular epithelial and interstitial cells, 
respectively).  
2. Hypothesis
Higher frequencies of immune-mediated kidney disease complications in South Africans, 
such as HIV-associated nephropathy (HIVAN), may be influenced by functional genetic 
variations in TGFB1. 
Aims and objectives 
Aim 1: To determine whether the African-specific variants in the regulatory region of TGFB1 
are functional 
Objectives 
• Perform haplotype analysis on the minor alleles of the TGFB1 promoter
• Generate six African-specific TGFB1 haplotypes using site-directed mutagenesis
• Transiently transfect the six TGFB1 haplotypes in two renal cell lines using  a
reporter gene assay to measure basal and stimulated promoter activity
• Perform western blot analysis on primary dermal fibroblasts with known genotypes
and compare TGF-β1 and pSmad3 protein levels between the haplotypes at basal and
stimulated (rhTGF-β1) conditions
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• Co-transfect renal and fibroblast cell lines with the TGFB1 haplotypes and a HIV-tat
expression construct and compare its effect on basal TGFB1 promoter activity using a
reporter gene assay
Aim 2: To investigate whether the African variants have a potential role in HIV-associated 
kidney complications 
Objectives 
• Perform immunohistochemistry on 20 biopsies from patients with HIV-associated
nephropathy (HIVAN) and compare TGF-β1 positive staining patterns of HIV-
positive and –negative control biopsies without HIVAN
• Perform genotyping for the functional African-specific -387 C>T TGFB1 variant as
well as the APOL1 risk variants for the 20 individuals with HIVAN
3. Materials and Methods
3.1. Patients 
DNA was extracted from peripheral blood samples of HIV-positive South Africans with 
African-ancestry who presented with HIV-associated nephropathy (HIVAN) at Groote 
Schuur hospital (n=20 patients). HIVAN was previously characterised by clinicians at Groote 
Schuur hospital and histopathological features were defined as a constellation of glomerular, 
interstitial and tubular abnormalities (Wearne et al. 2012). These blood samples were 
genotyped for the variants in the upstream regulatory region of TGFB1 (5’UTR) (as 
previously described by Nel et al., 2015) as well as G1 and G2 risk alleles in APOL1.  
This study was approved by the University of Cape Town Health Sciences Faculty Research 
Ethics committee (HREC#591/2014 for TGF-β1 and #491/2008 for HIVAN). Informed 
consent was obtained for all participants.  
3.2. Sequencing of the APOL1 variants 
Sequencing primers were designed to sequence the end of the APOL1 gene (exon 6, 
chromosome 22) based on previously used primer sets (forward and reverse primers) from 
Canaud et al. (2013). Unfortunately, these primers yielded “background noise” or odd peaks 
on the chromatogram, which suggests that there was non-specific binding of the primers. 
	 20 
Therefore, a new primer set was designed by Inqaba Biotechnical Industries (Pty) Ltd (South 
Africa) and the Sanger sequencing approach was used to sequence the HIVAN samples for 
APOL1. Chromatograms were analysed using the CLC Bio Main workbench version primer 
design tool.  
3.3. Haplotype analysis 
Four African-specific single nucleotide polymorphisms (SNPs) have been identified in the 
TGFB1 regulatory region (TGFB1 -1287 G>A, -1154 C>T, -387 C>T and -14G>A) are 
shown in figure 1.3. Haplotype analysis of the unphased genotyping data from the 1000 
Genomes Project Phase 3 European and African super-populations was performed in 
Haploview (Broad Institute, MIT and Harvard) using the confidence interval (nearest 
neighbour) algorithm described by (Gabriel et al. 2002; Barrett et al. 2005). Additionally, in 
this thesis the default confidence bound cut-offs were customized to only include TGFB1 -
1347C>T, -1298G>A, -1154C>T, -387C>T and -14G>A polymorphic sites. The linkage 
disequilibrium plot for these sites are shown in figure 4.1B.  
 
The genotyping data from South Africans with African genetic ancestry (n=344 
chromosomes) previously genotyped and reported (Nel et al., 2015) were used in TGFB1 




3.4. TGFB1 promoter-reporter gene constructs 
As described in Nel et al. (2015) a 2856 base-pair fragment of the TGFB1 regulatory region 
was cloned upstream of a luciferase reporter gene in the pGL3 Basic Firefly Luciferase 
Reporter Vector (Promega, Madison, WI, USA). The cloned TGFB1 promoter fragment was 
amplified from genomic DNA and corresponds with base pairs -2750 to +106 numbered 
relative to the ATG translation start site and is identical to that of the NCBI reference 
sequence NC_000019.10 from nucleotide positions 41352723 to 41355915 (chromosome 19, 
GRCh38.p2 primary assembly 12-03-15).  This promoter drives expression of the firefly 
(Photinus pyralis) and renilla reporter (Renilla reniformis) enzymes by addition of Luciferase 
Assay Reagent II (LARII) to generate a stable luminescent signal (firefly) which is quantified 
before addition of the Stop & Glo® reagent to measure the renilla reaction (Promega Dual-













Figure 3.1: pGL3 Basic Firefly reporter vector construct. The diagram depicts the position of 
the Ampicillin resistance gene (Ampr), multiple cloning site (upstream of SV40 promoter), 
and the luciferase gene (luc+). The luciferase gene lies downstream of the SV40 promoter 
and it is in this region where the TGFB1 promoter sequence was cloned. Image sourced from: 
https://worldwide.promega.com/products/reporter-assays-and-transfection/reporter-vectors-
and-cell-lines/pgl3-luciferase-reporter-vectors/. 
3.5. Plasmid constructs 
The pRL-TK vector/renilla luciferase vector (Promega, Madison, WI, USA) was used as an 
internal control for transfection efficiency. To create the various TGFB1 promoter haplotype 
constructs, the -1347 C>T, -1287 G>A, -1154 C>T, -387 C>T and -14 G>A promoter 
polymorphisms were introduced into the cloned TGFB1 promoter reporter construct template 
by site-directed mutagenesis using the QuickChange kit (Stratagene, La Jolla, CA, USA). 
This was done sequentially to generate TGFB1 promoter haplotypes H-1 to H-6 as shown in 
figure 4.1C.  
 
3.5.1. Polymerase chain reaction (PCR) and Dpn1 digestion 
Point mutations were introduced into the TGFB1 promoter reporter construct using site-
directed mutagenesis, appropriate primer pairs were used to create the desired mutations. In 
the site-directed mutagenesis approach, two products are produced during a polymerase chain 
reaction (PCR), one of which is the mutated plasmid achieved by addition of site-directed 
mutagenesis primers that contain the desired point mutation. The second product is the 
parental template DNA, which will be digested by the endonuclease Dpn1. Primers were 
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designed using the QuickChange Primer Design Tool accessible here: 
www.genomics.agilent.com/primerDesignProgram.jsp 
 
Table 3.1: Site-directed mutagenesis primers used to introduce each of the TGFB1 SNPs to 
create the TGFB1 promoter haplotypes  
Site and direction Primer sequence 5’ to 3’ 
-1347 C>T forward GAGGACTGGGAAGGTAGGAAGTCCACAGGACAACGGG 
-1347 C>T reverse CTCCTGACCCTTCCATCCTTCAGGTGTCCTGTTGCCC 
-1287 G>A forward AGAAGAGGGTTTGTCAACATGGGGGCCTCC 
-1287 G>A reverse GGAGGCCCCCATGTTGACAAACCCTCTTCT 
-1154 C>T forward GCGGGCGGTATGGGTCACCAGAGAAAG 
-1154 C>T reverse CTTTCTCTGGTGACCCATACCGCCCGC 
-387 C>T forward TCGCCGACCCGGCTTCCCGCAAAG 
-387 C>T reverse CTTTGCGGGAAGCCGGGTCGGCGA 
-14 G>A forward GGAGGCGGCGTCCCCCGGCAC 
-14 G>A reverse GTGCCGGGGGACGCCGCCTCC 
 
Capital letters indicate nucleobases where A represents Adenine, G represents Guanine, C 
represents Cytosine and T represents Thymine.  
 
The standard PCR mix contained: 2x KAPA HiFi Hotstart Ready Mix, consisting of DNA 
polymerase (Kapa Biosystems, Cape Town, South Africa), 10ng DNA template, 10µM 
forward primer and 10µM reverse primer, made up in a total volume of 25µl. The parameters 
for the PCR amplification was: 2 minutes (min) at 95°C for 1 cycle, 20 seconds (sec) at 98°C, 
15 sec at 65°C, 4 min at 72°C, for 16 cycles. PCR was performed using an Applied 
Biosystems 2720 Thermal cycler. The PCR products were purified using the QIAquick PCR 
Purification Kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. The 
PCR product was first assessed by agarose gel electrophoresis (appendix) to confirm 
successful amplification and then purified using 1µl Dpn1 endonuclease (10U/µl) for 1 hour 
at 37°C. This digestion of the parental DNA was done in order to allow for selection of the 
DNA containing the mutation. The digest was followed by heat inactivation of the 
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endonuclease Dpn1 at 80°C for 20min. Samples were stored at 4°C and used for 
transformation experiments on the same day. 
 
3.5.2. Sequence verification  
After the Dpn1 digest, a small sample of the TGFB1 promoter constructs generated by SDM 
were genotyped by for the TGFB1 promoter variants. The Sanger sequencing approach was 
used by Inqaba Biotechnical Industries (Pty) Ltd (South Africa) in order to verify that the 
point mutations were successfully introduced during SDM. Sequencing primers were 
designed based on the principles of primer walking, where primers are designed 
consecutively to extend along an unknown sequence. Primers were designed using the CLC 
Bio Main workbench version primer design tool. To account for dye blobs and mismatches 
that occur during the starting point of annealing, the primers were designed to anneal 100 bp 
upstream of the region of interest. Primer parameters were as follows: the length of the 
primers were between 16-21 base pairs with a melting temperature (Tm) of 51-59°C where 
the DNA:primer complex will dissociate and become single stranded, guanine-cytosine 
content (GC content) of 40-60% which determines the stability of the primer and a guanine or 
a cytosine nucleic acid base on both ends.  
 










JoySeq3F CTATCGCCTGCACACA 54.3 56%  -1347 C>T, -1287 
G>A and -1154 
C>T 
JoySeq4F CTGGTCCTCTTTCTCTG 53.23 53% * -387 C>T 
JoySeq2R AAGTCTTTGCCGGGAGG 56.69 56% ** -14 G>A 
Table 3.1 shows the specific parameters and sequences for each of the primers. The 
JoySeq4F primer reaction needed treatment with dimethyl sulphoxide (DMSO) due to the GC 
rich region (referenced by *). The JoySeq2R primer was modified (referenced **) to be 
degenerative at the site marked in red to enable recognition of either a C or a T base, as it 
falls over a single polymorphic site (TGFB1 -387 C>T).  
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3.5.3. DH5α competent bacterial cells 
Competent bacterial cells were generated by inoculation of Luria Broth (LB) (appendix) with 
the DH5α strain of E. coli. The culture was grown overnight, with shaking at 37°C. A small 
amount of the overnight culture was then used to inoculate 100ml of LB and incubated for 2-
3 hours until the bacterial cells reached log growth phase (defined as an OD595 reading of 0.5-
0.8). The culture was then centrifuged at 3000rpm for 10min and the supernatant discarded 
before the pellet was resuspended in ice-cold 100mM calcium chloride (CaCl2). The 
resuspended cells were kept on ice for 1 hour before centrifugation at 3000rpm for 10min at 
4°C, after which the supernatant was discarded. The pellet was resuspended in a final volume 
of 1ml 100mM CaCl2. Competent cells were kept overnight at 4°C before immediate use or 
stored in 50% glycerol (final volume 15%), snap-frozen in liquid nitrogen and kept at -80°C 
until use.  
 
3.5.4. Transformation 
20ng DNA was added to a thawed glycerol stock of competent DH5α E. coli cells and 
incubated on ice for 15 min. The cells and DNA were then subjected to heat shock at 42°C 
for 45 seconds before incubating on ice for 5min. This rendered the bacterial cell membrane 
permeable, allowing the DNA to move into the cells were it would later be expressed. LB 
broth was added to the competent cell-DNA mixture and incubated at 37°C at 200rpm for 
30min. The resuspension was then plated onto a LB agar plate containing ampicillin 
(100µg/ml) using aseptic spreading technique.  
 
The plates were inverted and incubated for 14-16 hours at 37°C. Antibiotics were added to 
allow for antibiotic selection in order to achieve single colony formation and for the selection 
of cells expressing the transformed plasmid. Negative controls containing untransformed 
bacterial cells were included to test whether the competent cells were not inherently antibiotic 
resistant. The single transformed colonies were used in small- and large-scale DNA 
preparations.  
3.5.5. Small-scale (mini) preparation of plasmid DNA 
Small-scale preparations were used to purify the plasmid DNA for further use in experiments 
and verification via Sanger sequencing. Following transformation, a single transformed 
colony was picked by sterile pipette tip or toothpick and used to inoculate a small volume of 
LB culture containing 1% ampicillin. The culture was grown at 200rmp and 37°C overnight 
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before being purified using the QIAprep® Spin Miniprep Kit (Qiagen, Hilden, Germany). 
Elutions were performed using the elution buffer (buffer EB, Qiagen, Hilden, Germany).  
 
The samples were run on a 1% agarose gel at 70V for 45 min in order to visualise the 
integrity of the DNA and to compare the plasmid to the appropriate positive control. Positive 
controls were used to evaluate specificity of primer binding. Verification of the point 
mutations were performed using the Sanger sequencing approach (Inqaba Biotechnical 
Industries (Pty) Ltd, Pretoria, South Africa). Unused DNA was stored at -20°C. 
3.5.6. Large-scale (maxi) preparation of plasmid DNA 
The large-scale DNA preparations were performed on selected mutant constructs for further 
use in luciferase assays. The Promega PureYield™ Plasmid Maxiprep system (Promega, 
Madison, WI, USA) was used according to the manufacturer’s instruction. Briefly: a single 
transformed colony from a LB ampicillin plate was picked with a sterile pipette tip/toothpick 
and used to inoculate a small volume of LB containing 1% ampicillin. The culture was grown 
for 8 hours at 200rmp and 37°C before 1ml was used to inoculate a bigger volume of LB with 
1% ampicillin. The culture was grown overnight at 200rpm and 37°C before it underwent 
centrifugation at 5000xg for 10 min at room temperature (RT) in a Beckman coulter Acanti J-
E centrifuge with a JA-10 rotor. The supernatant was discarded after centrifugation and the 
pellet was resuspended in Cell Resuspension Solution. Next, Cell Lysis Solution was added 
in order to lyse the cells and denature the chromosomal DNA. The tube was inverted and 
allowed to incubate for 3 min at RT before the addition of Neutralising Solution in order to 
neutralise the cell lysate and to allow for the chromosomal DNA to re-aggregate with cellular 
proteins. The tube was inverted several times to ensure precipitation of cellular debris before 
centrifugation at 7000xg for 30min at RT. This separated the chromosomal DNA, protein and 
cell debris from the rest of the solution containing plasmid DNA. The DNA was then purified 
by passing it through a PureYieldTM Maxi Binding Column attached to a PureYieldTM Maxi 
Clearing Column using a vacuum manifold and performing several washes until the DNA 
was successfully bound to the membrane. The membrane was dried before elutions were 
performed using pre-warmed nuclease free water and centrifugation at 2000xg for 5min at 
RT.  
 
DNA concentration and integrity was calculated and analysed by nanodrop (ND-1000 v3.5.2 
software, Inqaba Biotechnical Industries, Pretoria, South Africa) before maxipreps were 
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stored at -20°C and aliquots were prepared to minimize the impact of multiple freeze thaw 
cycles.  The purified plasmid DNA samples were run on a 1% agarose gel at 70V for 45 min 
to visualize the integrity of the DNA and to compare it to an appropriate positive control. 
 
3.6. Cell culture  
RCC4+VHL (human renal cell carcinoma stably transfected with pcDNA3-VHL), Caki-2 
(human clear cell renal cell carcinoma), HT1080 (human fibrosarcoma) and dermal fibroblast 
cells were cultured in Dulbecco’s Modified Eagle’s medium (DMEM) (Whitehead Scientific, 
Cape Town, South Africa) supplemented with 10% fetal bovine serum (FBS) (Scientific 
Group, Johannesburg, South Africa), 100U/ml penicillin and streptomycin (Pen/Strep) 
(Sigma-Aldrich, St Louis, MO, USA). The FBS was added to provide the cells with 
nourishment and growth factors in order to proliferate. The antibiotics penicillin and 
streptomycin were added in order to prevent infection of the cell cultures. All cells were 
maintained in an incubator at 37°C (5% CO2 and 65% humidity). The medium was replaced 
every 2-3 days and sterile technique was practised when culturing the cells. Regular tests for 
mycoplasma infection were performed. 
 
3.6.1. Mycoplasma test 
Cells were grown on a coverslip for 3-5 days in antibiotic-free medium and then fixed using a 
1:3 mixture of glacial acetic acid and methanol for 5 sec. Following fixation, the cells were 
briefly rinsed with water before air-drying at RT for 5-10 min. The cells were then stained 
with a working solution of Hoechst (0.5µg/ml) for 10sec. The excess stain was washed off 
with water before mounting the coverslip onto a glass slide using mounting fluid (see 
appendix). The cells were then viewed by fluorescence microscopy using the Axiovert 
fluorescent microscope and software for analysis (Zeiss, Oberkochen, Germany). 
3.7. Luciferase assays 
3.7.1. Transfection 
RCC4+VHL cells were plated at 5 x104 cells per well and Caki-2 and HT1080 cells were 
plated at 7.5 x104 cells per well of a 12-well plate one day prior to transfection. Sixteen hours 
after plating cells were transiently transfected using the XtremeGENE HP DNA transfection 
reagent according to manufacturer’s instructions (Roche, Basel, Switzerland). The 
transfection reagent is comprised of lipids and acts by forming a complex with the transfected 
DNA, which is then transported into the cells. Dose curves were performed in all of the cell 
	 27 
lines with varying doses of TGFB1 promoter constructs in order to establish the optimal 
DNA concentrations for transfections. Each transfection and subsequent luciferase assay was 
performed in duplicate, where the pGL3-empty reporter plasmid and TGFB1 promoter 
constructs were transfected into the different cells.  
 
For co-transfection experiments, XtremeGene HP DNA transfection reagent was also used to 
transfect the relevant TGFB1 promoter haplotypes with 350ng pcDNA3.1-HIV tat expression 
construct made up to a total of 550ng DNA with the pcDNA3.1 empty vector. For all 
transfection experiments 50ng of the pRL-TK vector (Promega, Madison, WI, USA), which 
contains the HSV-thymidine kinase promoter driving the expression of a renilla reporter 
(Renilla reniformis), was used as an internal control. Unfortunately, the renilla reporter was 
independently regulated by the HIV tat construct and we therefor did not include the renilla 
luciferase values in our analysis. Instead β-galactosidase assays were used to account for 
transfection efficiency (see section 3.7.4)  
 
3.7.2. In vitro treatment of TGFB1 promoters with human recombinant TGF-β1 
RCC4+VHL and HT1080 cells were plated in 12-well plates as previously described (section 
3.7.1.) and transient transfection performed with H-ANC and H-AFR TGFB1 promoter 
haplotypes. The cells were serum-starved in medium containing 0,5% FBS and 1% Pen/Strep 
twenty-four hours before treatment with 5µg/ml recombinant human TGF-β1 (rhTGF-β1) 
(R&D Systems, MN, USA). Cells were subsequently treated with rhTGF-β1 for one or six 
hours, before harvesting with Passive Lysis Buffer (Promega, WI, USA). pRL-TK renilla 
reporter was used as an internal control and an empty vector control was also added in order 
to compare TGFB1 promoter activity responses. TGFB1 promoter activity was measured 
using a luminometer (Promega, Madison, WI, USA).  
3.7.3. Luciferase assays 
Luciferase assays were performed in duplicate using the Promega DUAL-Luciferase 
Reporter Assay System (Promega, WI, USA). The cells were harvested 30 hours post-
transfection and washed with ice-cold Phosphate Buffer Saline (PBS) (see appendix) before 
harvesting the cell lysates in Passive Lysis Buffer (PLB) (Promega, WI, USA). The PLB was 
prepared in a 1:5 dilution with nuclease free water, and after addition of the lysis buffer, the 
cells were scraped down using a syringe as explained in the Promega DUAL-Luciferase 
Reporter Assay System manufacturer instructions. Cell lysates were stored at -80°C for 14-16 
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hours and freeze-thawed to effectively lyse the cells. The reporter activity of the lysates was 
assayed and measured for both the firefly luciferase as well as renilla luciferase activity.  
 
Reporter activity is measured by the reaction of firefly luciferase enzyme catalysing the 
conversion of luciferin to oxyluciferin, which emits light that is measured by the 
luminometer. Renilla luciferase is then measured, which converts the co-elenterate-luciferin 
(coelenterazine) to coelenteramide in the presence of oxygen. The dual-luciferase reporter 
assay utilizes these reporter enzymes to simultaneously measure both the reporter gene 
activity of the transfected TGFB1 promoter construct as well as the renilla internal control.  
 
The lysates were centrifuged at 10 000xg for 2min to pellet the cell debris prior to use in the 
assay. The samples were then added to a 96-well luminometer plate before adding LARII 
(Promega, Madison, WI, USA). The light emitted by the firefly luciferase reaction was then 
measured and quantified by the luminometer (Thermo LabSystems, Luminoskan Ascent). 1x 
Stop & Glo buffer was then added to each sample to simultaneously quench the firefly 
luciferase reaction and initiate the renilla luciferase reaction. These values were also 
quantified and recorded by the luminometer using the Ascent Software 2.6 (Thermo Fisher 
Scientific, Waltham, MA, USA) as well as Microsoft Excel (Windows Vista). Relative 
luciferase activity values were normalised to the renilla activity to account for variation in 
transfection efficiency before making comparisons between the activity of the different 
TGFB1 promoter haplotypes. This normalisation was not performed for the HIV-tat co-
transfection experiments as the internal control pRL-TK was regulated by the pcDNA3.1-
HIV tat construct.  
 
3.7.4. β-galactosidase vector as internal control for transfection efficiency 
The pCMV β-galactosidase vector (Clontech Laboratories, Mountain View, CA, USA) was 
used as an internal control for transfection efficiency in the HIV tat co-transfection 
experiments. The pCMV β-galactosidase vector contains the cytomegalovirus promoter 
which drives the expression of a lacZ reporter plasmid. Cells were transfected as previously 
stated in section 3.7.1 and cultured for 48 hours. The cells were subsequently washed with 
1xPBS and fixed with 4% paraformaldehyde for 15min, followed by another wash before 
addition of the β-gal stain (see appendix) and incubated for 2-4 hours. The blue-white 
staining was monitored and recorded by light microscope. Images were taken 2-4 hours after 
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the stain was applied. The cells transfected with the β-galactosidase vector (presenting as 
blue from the reaction with β-gal stain) was quantified by counting 5-10 field of views before 
and after transfection and calculating the average amount of cells per view. Transfection 
efficiency was expressed as the percentage of cells that were positive/blue out of the total 














Figure 3.2: Light microscopy image of RCC4+VHL cells after two hours of incubation with 
the β-galactosidase stain. Figure is representative of what was observed in 2 independent 
experiments for both RCC4+VHL and HT1080 cells where ~30% of cells were transfected 
with the TGFB1 promoter constructs and β-galactosidase expression vector.  
3.8. Western blot analysis 
3.8.1. Protein harvesting  
Western blot analysis was performed to investigate the downstream effects of the African-
specific TGFB1 promoter variants on TGF-β1 and phosphorylated SMAD3 protein levels. To 
this end dermal fibroblasts from patients with known TGFB1 promoter haplotypes were plated 
at 2.5x104 cells per well of a 6-well plate and allowed to grow for 16-24 hours before 
treatment with 5µg/ml human recombinant TGF-β1 protein for 60 min. An untreated well of 
dermal fibroblasts was also included in the experiments to represent basal TGF-β1 and 
phosphor-SMAD3 protein expression for each of the TGFB1 promoter haplotypes. After 
treatment, the cells were harvested using trypsin/EDTA and then centrifuged at 4 000 rpm for 
5 min at 4°C before resuspension in ice-cold PBS. The samples were then centrifuged again at 
4 000 rpm for 4 min at 4°C before the pellet was resuspended in Radioimmunopercipitation 
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(RIPA) buffer (see appendix) to lyse the cells and extract the protein. The samples were spun 
down at 12 000 rpm for 20 min at 4°C before resuspension in RIPA buffer. The supernatant 
was subsequently transferred to respective new eppendorf tubes. Samples were stored in 
aliquots at -80°C until needed. 
 
3.8.2. Bicinchoninic acid assay  
Bicinchoninic acid assay (BCA assay) is a biochemical assay used to determine the total 
concentration of protein in a solution/sample. A BCA assay was performed for harvested 
protein from the dermal fibroblasts with the Pierce BCA Protein Assay Kit (Thermo Fisher 
Scientific, Waltham, MA, USA) as per manufacturer’s instructions. The samples were loaded 
on a microplate reader and readings were recorded with the RT-2100c software (Rayto Life 
and Analytical Sciences, Shenzhen, China). Standard curve analysis was subsequently 
performed in Microsoft Excel (Windows, 2010). Standard curve analysis is performed by 
substituting the values from the microplate reader into a predetermined linear regression 
equation (derived from protein samples with known concentrations) which then allows for 
the calculation of the concentration of the specific protein in the harvested sample. This 
concentration is then used to calculate the amount of protein present in the sample, which 
then allows for equal protein loading across the wells during SDS-PAGE (see below).  
 
3.8.3. Sodium-dodecyl-sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Thirty-five micrograms of protein from each untreated and rhTGF-β1 treated samples were 
solubilised in RIPA buffer and heated at 75°C for 10 min before electrophoresed on 1.5mm 
(thick) 10% resolving gels with a 5% stacking gel (see appendix). Biorad Mini PROTEAN© 
3 casting apparatus was used to cast the gels and Biorad running tanks were filled with 1x 
running buffer (see appendix). TGF-β1 is a 44kDa protein, phosphor-SMAD3 is a 52kDa 
protein and the loading control p38 is a 40kDa protein. p38 was used as a loading control 
because it is unaffected by changes in cell cycle which leaves similar levels of expression for 
all of the samples. Due to their close proximity due to similar size, two separate SDS-PAGE 
gels were run for the TGF-β1 or phosphor-SMAD3 protein and the loading control. 
Molecular weight markers were used to monitor protein separation (PageRuler Prestained 
Protein Ladder, 26616, Thermo Fisher Scientific, Waltham, MA, USA). The running tank 
was connected to a power pack (Biorad Powerpack 200) and proteins were electrophoresed at 
100V for 2 hours to separate the proteins sufficiently.  
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3.8.4. Nitrocellulose membrane transfer 
The electrophoresed proteins were transferred to a Hybond ECL nitrocellulose membrane 
(Amersham Biosciences, UK) that was cut to size by packing the gels into a ‘sandwich’ using 
a cassette and placed in ice cold transfer buffer (appendix) for 1.5 hours at 100V. The 
‘sandwich’ consisted of sponges, whattmann filter paper, the SDS-PAGE gel and the 
nitrocellulose membrane. After the membrane transfer, a Ponceau S stain was used to ensure 
the protein had transferred correctly and that equal loading could be observed.  
 
3.8.5. Detection and western blot analysis 
After the membrane transfer, the p38 and TGF-β1 blots were rinsed with PBS/Tween 
(appendix). The phosphor-SMAD3 blot was rinsed with TBS/Tween (appendix) and then 
blocked for one hour at RT with blocking buffer (appendix). The p38 blot was blocked with 
5% milk in PBS/Tween, whereas the TGF-β1 blot was blocked with 5% Bovine Serum 
Albumin (BSA) in PBS/Tween and the phosphor-SMAD3 blot was blocked with 5% milk in 
TBS/Tween. After blocking, the membranes were incubated overnight with their appropriate 
primary antibody dilutions at 4°C with gentle shaking. The p38 blot was incubated with a 
1:2000 dilution of rabbit polyclonal anti-p38 primary antibody (M0800, Sigma-Aldrich, St 
Louis, MO, USA), diluted in 5% milk PBS/Tween, whereas the TGF-β1 blot was incubated 
with a 1:500 dilution of mouse monoclonal anti-TGF-β1 primary antibody (MA517186, 
Separations, Johannesburg, South Africa) and the phosphor-SMAD3 blot was incubated with 
a 1:1000 dilution of rabbit polyclonal anti-Psmad3 primary antibody (C25A9, Cell 
Signalling, Danvers, MA, USA).  
 
After overnight incubation with the primary antibody, the membranes were rinsed as stated 
previously: the p38 and phosphor-SMAD3 membranes with PBS/Tween and the TGF-β1 
membrane with TBS/Tween. The membranes were subsequently incubated with their 
respective secondary antibodies at RT for 1 hour. The secondary antibodies were as follow: 
horseradish peroxidase-conjugated goat anti-rabbit secondary antibody (Biorad, Hercules, 
CA, USA) at 1:5000 for the p38 and phosphor-SMAD3 membranes and horseradish 
peroxidase-conjugated goat anti-mouse secondary antibody (Biorad, Hercules, CA, USA) at 
1:4000 for the TGF-β1 membrane.  
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After incubation with the secondary antibody, the membranes were rinsed and the signal was 
visualised by enhanced chemiluminescence (ECL) using WesternBright™ ECL (K-12045-
D50, Advansta, Menlo Park, CA, USA) in a 1:1 ratio. The ECL substrate was incubated on 
the blots at RT for 5 min before placing the membranes between two transparencies, with an 
x-ray film placed on top. The cassette was then closed and the emission of light caused by the 
oxidation of the detection reagent and the conjugated horseradish peroxidase was captured on 
the x-ray film by developing and fixing the blot. Densitometric analysis was performed to 
quantify the bands and to normalise the treated to the untreated sample for each of the 
TGFB1 promoter haplotypes by UnScan-it gel 6.1 software and Microsoft Excel (Windows, 
2010). All of the densitometric readings were first normalised to the loading control, p38, and 
then to the untreated control cells. Unpaired student’s t-test was used to compare basal and 
rhTGF-β1 stimulated protein responses between cells with different haplotypes.  
 
3.9. Immunohistochemistry of TGF-β1 on HIVAN patient renal biopsies 
3.9.1. Preparation of biopsies 
Formalin Fixed Paraffin Embedded (FFPE) renal biopsy slides from patients with HIV-
associated nephropathy (HIVAN) (n=19 biopsies) were cut and placed on microscope slides 
for staining with a monoclonal mouse anti-TGF-β1 antibody (MA5-17186, Thermo Fisher 
Scientific, Pierce Antibodies, Waltham, MA, USA).  
Immunohistochemistry was performed under the supervision of Subash Govender at the 
Division of Anatomical Pathology, University of Cape Town. The slides were placed on a 
heating block in order to allow the wax to melt prior to the de-waxing process. De-
waxing/deparaffinising consists of incubation of the the slides in three graded series of xylene 
for 5 minutes at a time, followed by 3 alcohol graded series for 3 min at a time prior to 
rinsing with running water for 5-10min. The de-waxing process was followed by antigen 
retrieval using Tris/EDTA (see appendix). Following the de-waxing process, antigen retrieval 
was performed in order to remove the cross-linking caused by the wax and to unmask the 
antigens. The antigen retrieval process was performed in a pressure cooker by boiling 
Tris/EDTA and inserting the slides to boil for 1 min and 30seconds. The slides were allowed 
to cool for 30 min before washing under running water for 5 min. Endogenous peroxidase 
was inhibited by incubation of the specimens in 3% Hydrogen peroxide (H2O2, Merck, 
Germany) for 10 min.  
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After washing in PBS for 10 min, the slides were covered with 5% goat-serum (DAKO, 
Glostrup, Denmark) for 15 min in order to block the remaining binding surface and prevent 
non-specific binding of the primary antibody. The excess goat-serum was wiped off without 
disturbing the tissue section before addition of the 1:500 dilution of primary antibody, mouse 
anti-TGF- β1. After one-hour incubation with primary antibody, the excess was wiped off 
without touching the tissue and sections were covered with the secondary antibody, DAKO 
anti-mouse (DAKO, Glostrup, Denmark), for 30 min. The nuclear stain, 3,3’-
Diaminobenzidine/DAB (DAKO, Glostrup, Denmark), was subsequently added to the 
sections for 10 min before washing in running water for 5 min. The slides were then placed in 
Haematoxylin stain for 2 min and then briefly placed in ammoniated water prior to washing 
in running water until the DAB stain turned blue. The sections were then dehydrated using a 
graded series of alcohol and xylene before being mounted onto a cover slip with entallen 
(Merck, Darmstadt, Germany). The slides were then viewed under a light microscope at 200x 
and 400x magnification, with images taken by light microscopy.  
 
3.9.2. Scoring of the stained tissues  
A semi-quantitative “histo”-score (H-score) was assigned to each of the biopsies: the 
intensity of the stain is multiplied by the percentage of cells that stain positive for the tubules 
and the interstitium separately. The H-scores, ranging from 0-200, was then compared 
between HIVAN, HIV-negative and HIV-positive control groups. The interquartile ranges 
and median was calculated for the Masson’s stain for fibrosis. The Masson’s stain for fibrosis 
or Masson’s trichrome stain is used in order to distinguish cells from the surrounding 
connective tissue. Blue staining indicates the connective tissue/collagen and allows for the 
grading of the severity of fibrosis, accumulation of extracellular matrix proteins such as 
collagen.  
 
3.10. Statistical analysis 
Raw luciferase assay data was analysed in Microsoft Excel. Luciferase values were 
calculated for each repeat and averaged to account for changes in transfection efficiency for 
each technical repeat by calculating the firefly to renilla ratios. All four of the TGFB1 
promoter activity was first normalized to pGL3-basic and then the fold activation/repression 
was normalized to the most common H-5 TGFB1 promoter activity. For transient and co-
transfection experiments, the fold activations and standard deviations were pooled across 
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biological repeats and were summarized in one graph. TGFB1 promoter activity was 
compared with unpaired student’s t-tests between haplotypes, while paired student’s t-tests 
were used for comparisons between the different treatment time points for each of the TGFB1 
promoter constructs. Paired student’s t-tests were also used to compare basal TGFB1 
promoter activity between all of the different TGFB1 haplotypes. Densitometric readings 
were used to calculate the mean and standard error of the mean (SEM) for each of the blots 
before pooling the results from three or more biological repeats into one graph. In the case of 
an outlier (skewed results) the interquartile range and median was calculated as per non-
parametric data analysis. Fisher’s exact test or mid P-exact was used to calculate statistical 
significant differences in proportional differences between the APOL1 minor allele 
frequencies of the Cape Town HIVAN and population control biopsies using OpenEpi 
(http://www.openepi.com/TwobyTwo/TwobyTwo.htm). The odds ratio was also calculated in 
order to compare the relative odds of HIVAN occurring together with the APOL1 variants. 
The 95% confidence interval was also calculated where there is a 95% certainty that the 
population mean occurs within the range. P values of ≤0.05 were regarded as statistically 
significant.  
4. Results 
4.1. African-specific TGFB1 promoter haplotype analysis  
Previously, TGFB1 regulatory region loci minor allele frequencies (MAF) of population 
control cohorts from Cape Town and Soweto (n=344 chromosomes) were compared to the 
European (n=1006 chromosomes) and ‘African’ (n=1322 chromosomes) samples in the 1000 
Genomes Project Phase 3 dataset (Nel et al., 2015). Nel et al. (2015) found that the South 
Africans had significantly different alleles frequencies (MAF 0.17) for the African-specific 
variants compared to the 1000 Genomes African dataset comprising pooled African 
Americans, East- and West-Africans (MAF ~0.05). Importantly they do not occur in a 
European dataset (black bars in figure 4.1A) In order to ascertain which haplotypes are most 
common amongst Africans, and specifically South Africans, this data was used to perform 
haplotype analysis on the TGFB1 promoter variants, including the ancestral rs1800469 (-
1347 C>T) and the African-specific rs11466314 (-1287 G>A), rs35318502 (-1154 C>T), 
rs11466316 (-387 C>T) and rs9282871 (-14 G>A) loci (n=344 chromosomes). 
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Haploview software was used for this analysis which utilizes nearest-neighbour 
algorithm/confidence interval as described by Gabriel et al. 2002. Similar to previous results, 
figure 4.1B showed that the -1287 G>A and -1154 C>T polymorphisms are in tight linkage 
disequilibrium (LD) with an r2 value of 0.7 (as represented by % as shown in figure 4.1B) 
(Nel et al. 2015). The -387 C>T and -14 G>A polymorphisms were shown to co-occur to a 
greater degree (r2= 0.86, figure 4.1B). Interestingly, the African-specific variants all co-
occurred with the lower expressing ancestral haplotype containing the TGFB1 -1347 C allele 
as shown by the regression analysis (r2 in the white section of the linkage disequilibrium plot 
(r2≤0.02, figure 4.1B).  
 
As previously discussed, the literature has focussed on ancestral haplotypes with the 
functional TGFB1 -1347 C>T (commonly referred to in the literature as -509 C>T). The 
common ancestral TGFB1 promoter haplotype, termed H-5 in this thesis, represents the 
lower expressing ancestral haplotype with the -1347 C allele; this haplotype is the most 
common occurring TGFB1 promoter haplotype in African and European populations 
(Haplotype frequency of ~80%). The TGFB1 promoter H-6 represents the higher expressing 
ancestral haplotype with the -1347 T allele; this haplotype is the second most common 
occurring TGFB1 promoter haplotype in Africans and Europeans with an allele frequency of 
~20-30%, respectively. Interestingly the African-specific variants all co-occur with the lower 
expressing ancestral haplotype containing the TGFB1 -1347 C and are represented in Figure 





























Figure 4.1: A) Amended graph of minor allele frequencies published in Nel et al. (2015) for 
the TGFB1 -1347 C>T and the African-specific single nucleotide polymorphisms in the 1000 
Genomes Project AFR (n=1322 chromosomes), 1000 Genomes Project EUR (n=1006 
chromosomes) and South African (n=344 chromosomes) dataset. The dotted line at 5% 
indicates the cut-off for rare variants. Significant differences between the population groups 
are indicated by p-values. B) Linkage disequilibrium (LD) plot for the 5 polymorphic sites in 
the TGFB1 regulatory region. Numbers within the diamonds indicate r2 values as 
percentages. r2=0 in white, 0<r2<1= shades of grey and r2=1 in black. C) Table showing the 
six biologically relevant haplotypes in our group via haplotype analysis using Haploview 
	 37 
software. Minor variants shown in bold. *Estimated frequency of African TGFB1 promoter 
haplotypes in a South African cohort as very rare haplotypes have been excluded from the 
analysis. 
 
4.2. Functionality of the African-specific TGFB1 promoter haplotypes 
Previously other groups investigated basal TGFB1 promoter activity with a promoter that did 
not include the extended regulatory region which may impact on the “full length promoter” 
activity (Figure 1.3B and C). Nel et al. (2015) created an extended length human TGFB1 
promoter cloned into a luciferase reporter construct and found that the African-specific -387 
T was functional and resulted in a 5-fold loss in basal promoter activity in cell lines of 
fibroblasts and muscle origin (Nel et al. 2015). As a follow-on, one of the main objectives in 
this work was to investigate whether the TGF-β1 pathway was contributing to the increased 
incidence of HIV-associated kidney disease in South Africans. This part of the study aimed to 
investigate the four African-specific TGFB1 promoter polymorphisms and their impact on 
basal TGFB1 promoter activity in renal cells.  
 
To this end, luciferase promoter reporter constructs of H-1 to H-6, produced as described in 
section 3.5. were transiently transfected into RCC4+VHL human renal cell carcinoma and 
Caki-2 human clear cell renal carcinoma cells and luciferase activity was measured. Relative 
luciferase values were normalised to pRL TK renilla activity, and then normalised to the 
empty pGL3-vector before any comparisons. These values were represented as fold 
repression or activation of the promoter activity and the pooled results of ≥3 independent 
experiments each performed in duplicate are shown in the bar graphs in figure 4.2. 
 
Results show in two cell lines of renal origin that there is no difference between the basal 
TGFB1 promoter activity of the common ancestral -1347 C (H-5) or less frequent -1347 T 
(H-6) haplotypes (pooled results of 3 independent experiments shown in figure 4.2, 
RCC4+VHL p=0.88 and Caki-2 p=0.82). Previously Nel et al. (2015) and others showed that 
the common -1347 C allele is the lower expressing allele in human fibrosarcoma and lung 
carcinoma cells, respectively, with a 2-3-fold difference in basal TGFB1 promoter activity 
compared to the -1347 T allele (Shah, Hurley, et al. 2006; Nel et al. 2015). Due to the fact 
that no ‘higher’ and ‘lower’ expressing haplotype containing the -1347 C or T alleles were 
observed, subsequent experiments focused on the -1347 C containing haplotype, i.e. with or  
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without the African-specific variants. Because the African-specific variants do not occur with 
the -1347 T allele (see LD plot figure 4.1B) and only with the -1347 C allele, and this is the 
common ancestral haplotype, this haplotype may be referred to as the ancestral (H-ANC) 
TGFB1 promoter haplotype in subsequent experiments.  
 
The results revealed that having one or more African-specific variant on the backbone of the 
H-5/H-ANC haplotype resulted in 70-80% (~5-fold) loss of basal promoter activity in renal 
cells (Figure 4.2). Despite TGFB1 -1287 G>A and -1154 C>T as well as the -387 C>T and -
14 G>A SNPs being in tight LD with each other, the repressive effect is largely attributed to 
the -387 T variant which is present in H-1 to H-4. Addition of the other African-specific 
polymorphisms did not result in any additional repression of basal promoter activity in the 
Caki-2 cells as they all have the -1347 C and -387 T (Figure 4.2B, H-2 through H-4). 
Although there was a difference between the H-1 and H-4 in the RCC4+VHL cell line where 
the -1287 A (H-4) resulted in a 1.6-fold decrease in activity compared to H-1 (p=0.03), the 
overall impression is that the rare H-4 promoter activity is prominently influenced by the -
387 T variant.  
 
In conclusion, this study has shown that the African-specific haplotypes (promoter haplotype 
H-1 to H-4, subsequently referred to as H-AFR in this thesis) results in a 5-fold repression of 
TGFB1 promoter activity in two renal cell lines when compared to the common ancestral 
haplotype (H-ANC/H-5). Results also show that TGFB1 promoter activity is similar between 
the African haplotypes and that the repressive effect can be attributed to the -387 T variant 
present in all four African haplotypes. In addition, in this extended TGFB1 promoter, no 
difference was found in the promoter activity in haplotypes containing either -1347 C or T 
alleles in cell lines of kidney origin.  
 
4.3. The effect of exogenous TGF-β1 on the TGFB1 regulatory region  
As previously discussed, renal cells may respond to autocrine and paracrine TGF-β1 signals 
during chronic kidney injury such as with HIV-infection. TGF-β1 results in phagocyte 
recruitment and the transformation of tubular epithelial cells into myofibroblasts, both of 
which in turn result in increased TGF-β1 production. In the previous section results showed 
that H-AFR (H-1 to H-4) have similar basal TGFB1 responses, but lower than H-ANC. In 
this part of the study the difference in response to TGF-β1 auto-induction for both the H-
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ANC (ancestral) and H-AFR (‘African’ -387 T containing variant) TGFB1 promoter 
haplotypes were investigated.  
 
After treatment with 5µg/ml recombinant human TGF-β1 (rhTGF-β1) for 1 hour and 6 hours 
we compared the relative change of treated compared to basal promoter activity in a kidney 
(RCC4+VHL) and fibroblast (HT1080) cell line. The kidney cell line was chosen to represent 
the renal tubules while the fibroblast cell line was chosen to represent the renal interstitium. 
RCC4+VHL and HT1080 cell lines were transiently transfected for 30 hours with TGFB1 
promoter haplotypes H-ANC and H-AFR and serum-starved for 16 hours prior to harvesting. 
Luciferase activity was measured and the fold changes calculated relative to each haplotype 
untreated before comparing the fold changes between haplotypes and between cell lines. 
 
 In both the RCC4+VHL and HT1080 cells the basal TGFB1 promoter activity for H-ANC 
and H-AFR was significantly different (p<10-4, refer to figure 4.3A and B). In the kidney 
cells, two independent experiments were performed at the 1-hour time points and four 
independent experiments for 6-hour treatment periods for both the H-ANC and H-AFR 
haplotypes (pooled results in figure 4.3). However, due to poor transfection efficiency, only 
one H-ANC experimental results at 1-hour were included in the analysis. Results showed that 
TGFB1 H-ANC did not respond significantly to treatment with rhTGF-β1 at 1 and 6 hours 
compared to untreated (p>0.05, figure 4.3A). The H-AFR showed a small but consistent 
response to 6-hour treatment with rhTGF-β1 (1.2-fold, SEM ±0.02, p=0.008, figure 4.3A).  
 
Although a similar trend was seen for H-AFR at 1-hour treatment with rhTGF-β1, only two 
experiments were performed and therefore it was not significantly different compared to 
untreated (1.4 fold, SEM ±0.06, p>0.05). 
 
In the fibroblast cell line (HT1080) four independent experiments showed a trend toward the 
H-ANC promoter being more responsive to stimulation than the H-AFR haplotype (Figure 
4.3B). After 1-hour of rhTGF-β1, H-ANC showed a trend towards increased promoter 
activity (1.2-fold, SEM ±0.004, p=0.07), but no significant change after 6 hours of treatment 
(SEM ±0.01, p=0.4) when compared to basal H-ANC activity (Figure 4.3B). There was very 
little or no response for the TGFB1 H-AFR haplotype after 1 and 6 hour treatments with 
rhTGF-β1 when compared to basal H-AFR promoter activity (p=0.8, figure 4.3B). 
	 41 




F-β1 does not consistently activate the TG
FB1 prom
oters in kidney (A


















frican’ -387 T containing variant) TG
FB1 prom
oter haplotypes and serum








F-β1) for 1 hour and 6 hours before harvesting. Controls w
ere not treated. Luciferase activity w
as 
m
easured 30 hours follow
ing transient transfection and expressed as the ratio of firefly to renilla luciferase activity for each of the haplotypes. pRL 
renilla reporter w
as used to control for transfection efficiency. These are pooled results of ≥2 independent experim





C in the RCC
4+V
H
L cell line), each perform
ed in duplicate. Statistical differences (including trends) are show




ed for treated versus untreated for each of the haplotypes, error bars standard error of the m
ean (SEM
). 















Taken together rhTGF-β1 treatment of cells as an indicator of the TGF-β1 autocrine pathway 
did not consistently activate the TGFB1 promoters although their responses were marginally 
different between cell types. The TGFB1 promoter haplotype containing the -387 T variant 
(H-AFR) is possibly more responsive to TGF-β1 stimulation in the kidney cell line but 
showed little or no response in the fibroblast cell line. 
4.4. Investigating basal TGF-β1 protein expression in human dermal fibroblasts 
Western blot analysis was performed on the fibroblasts of patients with known TGFB1 
promoter haplotypes in order to determine whether the reduced TGFB1 promoter activity 
observed in the African-specific TGFB1 promoter haplotypes were also reflected downstream 
at the protein level. Dermal fibroblasts were also stimulated with 5µg/ml rhTGF-β1 in order 
to compare the results to those in section 4.3 above. 
 
The human dermal fibroblasts were plated and treated with rhTGF-β1 for 1 hour while 
controls were left untreated before subjecting the harvested protein to SDS-PAGE gel 
analysis and western blotting. Four independent experiments were performed to assess basal 
TGF-β1 protein expression using the fibroblasts of three individuals with H-ANC and one 
individual with H-AFR. Densitometric analysis revealed that cells with TGFB1 H-AFR 
showed on average 47% lower basal TGF-β1 expression levels (consistent repression in 3 of 
4 biological repeats, p=0.04).  
 
However, there was an outlier; including all four results produced a median of 0.58 or 58% 
repression but broad interquartile range (IQR) 0.3;1.3 when compared to the common 
ancestral (H-ANC) haplotype (representative bar graph plotted with mean and standard 
deviation shown in figure 4.4A). 
 
In figure 4.4B results show that there was no difference in response to auto-induction, via 
rhTGF-β1, between H-ANC and H-AFR TGFB1 promoters based upon five independent 
experiments (p=0.27). The H-ANC cells responded to stimulation, albeit inconsistently, on 
average activating 3–fold after 1 hour of treatment (median 1.2; IQR 1;3.5). In contrast, the 
H-AFR cells containing the -387 T variant consistently showed no response to stimulation 
(mean/median=1; IQR 0.9;1.1). In figure 4.4C two representative western blots are shown for 
the five experiments with densitometric readings reflecting the variation at basal and 





















Figure 4.4: Basal and stimulated TGF-β1 protein expression levels in human dermal fibroblast 
cells with known genotypes. (A) Cells with the -387 T containing TGFB1 promoter (H-AFR) 
reduces basal TGF-β1 protein expression by 47% in human dermal fibroblasts. Protein from 
human dermal fibroblasts of patients with known genotypes were harvested in RIPA buffer before 
being subjected to SDS-PAGE analysis. These are pooled results from four independent 
experiments with H-ANC (cells with -1347 C)(n=3 different patient dermal fibroblast cells) and 
H-AFR (n=1 patient dermal fibroblast cells) cells. Densitometric analysis was performed and the 
ratio of TGF-β1 to the loading control, p38, is expressed as fold change of H-ANC relative to H-
AFR, one experiment was excluded as an outlier. Statistical differences are shown for basal TGF-
β1 expression for H-AFR relative to H-ANC. Bar graph with mean and standard deviation (SD). 
(B) Cells with the H-AFR TGFB1 promoter consistently does not respond to 1-hour stimulation 
with rhTGF-β1. Human dermal fibroblasts were serum-starved 24 hours prior to treatment with 
5µg/ml rhTGF-β1 for 1 hour. Controls were not treated. Protein was subjected to SDS-PAGE and 
western blot analysis. This graph is representative of five independent experiments with H-ANC 
(n=2 different patient dermal fibroblast cells) and H-AFR (n=1 patient dermal fibroblast cells) 
cells. Statistical analysis was performed using a student's two-tailed t-test for H-ANC cells 
relative to H-AFR. Densitometric analysis was performed and the fold activation is expressed as 
treated over untreated for each of the data points. Bar graph with mean and SD. C) Two western 
blots representative of five independent experiments. Densitometric readings expressed as the 
ratio of TGF-β1 protein to the p38 loading control.   
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In conclusion, the repressive effect observed with the TGFB1 -387 T promoter, compared to 
cells with the common ancestral promoter haplotype, was also observed at basal protein 
expression levels. Results are showed that cells with H-ANC do not consistently respond to 
autocrine stimulation but those with the H-AFR haplotype consistently show very little or no 
response to rhTGF-β1 after 1 hour.   
 
4.5. Phosphorylated Smad3 levels in human dermal fibroblasts 
The phosphorylation of Smad3 is one of the first steps in the TGF-β1 canonical pathway. 
Smad3 is a well-known transcriptional modulator activated by TGF-β1 signalling and is also 
known for its role in renal TGFβ-induced apoptosis. In order to investigate the effects of the 
TGFB1 promoter haplotypes western blot analysis was performed on human dermal 
















Figure 4.5: Basal and stimulated phosphorylated Smad 3 (pSmad3) protein expression levels in 
human dermal fibroblast cells with known genotypes. (A) Similar basal pSmad3 levels for cells 
with H-ANC (TGFB1 -1347 C) and H-AFR (containing TGFB1 -387 T) TGFB1 promoters in 
human dermal fibroblasts. Protein was harvested from human dermal fibroblasts of patients with 
known genotypes and subjected to SDS-PAGE and western blot analysis. The bar graph with 
mean and standard deviation (SD) are pooled results from two independent experiments with H-
ANC (n=1 patient dermal fibroblast cells) and H-AFR (n=3 different patient dermal fibroblast 
cells) cells. Densitometric analysis was performed and the ratio of TGF-β1 protein to the loading 
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control, p38, is expressed as the fold change of H-ANC relative to H-AFR. Statistical trend is 
shown for basal pSmad3 expression. (B) Similar upregulation for cells with H-ANC and H-AFR 
TGFB1 promoters are observed in response to 1-hour treatment with rhTGF-β1. Human dermal 
fibroblasts were serum-starved 24 hours prior to treatment with 5µg/ml rhTGF-β1 for 1 hour. 
Controls were not treated. Protein was harvested and subjected to SDS-PAGE and western blot 
analysis. The bar graph with mean and SD is representative of pooled results from seven 
independent experiments with H-ANC (n=5 different patient dermal fibroblast cells) and H-AFR 
(n=3 different patient dermal fibroblast cells) cells. Densitometric analysis was performed and the 
fold change is expressed as treated over basal/untreated for cells with the two TGFB1 promoters. 
A representative western blot is shown for seven independent experiments with densitometric 
readings expressed as the ratio of pSmad3 protein to the p38 loading control. 
 
As in section 4.4 the human dermal fibroblasts were treated with 5µg/ml rhTGF-β1 for 1 
hour. Two independent experiments were performed for basal phosphorylated Smad3 
(pSmad3) protein levels (H-ANC, n=1 patient dermal fibroblast cells; H-AFR, n=3 different 
patient dermal fibroblast cells) (Figure 4.5A). Western blot analysis revealed that there was 
no consistent difference in basal pSmad3 protein levels between cells with H-AFR when 
compared to H-ANC (fold change calculated on densitometric readings, p=0.24). In response 
to 1-hour treatment with rhTGF-β1 a similar upregulation in pSmad3 levels in both H-ANC 
and H-AFR cells was found, albeit inconsistently; the average activation of pSMAD3 levels 
was 12-fold for both H-ANC and H-AFR cells (SD ±19 and 11, respectively; p=0.92) (Figure 
4.5B).  
 
In conclusion this part of the study has shown that the basal pSmad3 levels as well as the 
pSmad3 response to stimulation with rhTGF-β1 were not different between patients who 
have the common ancestral (H-ANC) or African-specific TGFB1 haplotype (H-AFR). Both 
African and ancestral TGFB1 promoter haplotypes responded to the autocrine rhTGF-β1 
stimulus as evidenced by pSmad3 activation in the TGF-β1 canonical pathway. These results 
imply that TGF-β1 autocrine signalling is normal until pSmad3 enters the nucleus where cells 
with the TGFB1 -387 T allele have 5-fold repression of TGFB1 promoter activity compared 
to cells with the -387 C. 
 
4.6. HIV Tat protein activates the TGFB1 promoter haplotypes  
Because of the similar and 12-fold activation in pSmad3 levels in response to rhTGF-β1 
stimulation in both H-ANC and H-AFR promoters and because the TGF-β1 pathway has 
been implicated in the pathogenesis of HIVAN, the effect of intracellular HIV Tat on the 
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TGFB1 promoter haplotypes was investigated. To this end co-transfection experiments with a 
HIV Tat expression vector in RCC4+VHL human renal carcinoma cell line as well as a 
HT1080 human fibrosarcoma cell lines was performed.  
 
The H-AFR promoter together with both the ancestral (-1347 C) H-5 and less common (-
1347 T) H-6 TGFB1 promoter haplotypes were co-transfected with 350ng HIV Tat 
expression vector (pcDNA-HIV Tat) (provided by Dr Shaheen Mowla) and promoter activity 
measured before comparing the effect between haplotypes. Because Nel et al. (2015) 
reported that TGFB1 H-6 (-1347 T, pHap-4 in Nel et al., 2015) showed increased promoter 
activity compared to ancestral TGFB1 H-5 haplotype in fibrosarcoma cells, unlike this work 
in renal cells, both H-5 and H-6 were used in these experiments. An empty-vector control 
(pcDNA 3.1) was included in order to normalise and express the fold change relative to basal 
promoter activity for each of the TGFB1 promoters. A pRL-TK renilla construct was also 
included for internal control of transfection efficiency. It is important to note that addition of 
the HIV Tat expression construct resulted in a ~3-fold increase in pRL-TK renilla luciferase 
values when compared to the cells with the empty vector control. This indicated independent 
regulation of the renilla construct by the HIV Tat protein and therefore the renilla values 
could not be used to control for transfection efficiency. Instead the firefly luciferase values 
were used and β-galactosidase assays were performed to control for transfection efficiency 
(refer to methods and materials section 3.7.4).  
 
In the RCC4+VHL cell line all three TGFB1 promoters similarly activated in response to 
HIV Tat compared to basal levels; the TGFB1 H-6 promoter had a 1.5-fold increase (p=0.04), 
TGFB1 H-5 showed 1.6-fold (p<10-5) and H-AFR showed 1.8-fold (p=0.004) (Figure 4.6A). 
In at least 3 independent experiments in HT1080 cells, the H-6 haplotype showed no 
response to HIV Tat protein (1.2-fold, p=0.2) while the more common H-5 and the H-AFR 
haplotype both showed increased promoter activity in the presence of HIV Tat compared to 
basal promoter activity (H-5, 2-fold increase; p=0.009, H-AFR 1.4-fold increase; p=0.0004). 
There was a trend suggesting that the H-5 haplotype is more responsive than the H-6 
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In conclusion these results have shown a significant and similar increase in TGFB1 promoter 
activity in response to HIV Tat in all three the TGFB1 haplotypes in renal cells. In the 
fibroblast cells the responses were more variable depending on the promoter haplotype. There 
was a greater activation response to HIV Tat in the most common H-5 promoter, whereas the 
H-AFR and H-6 showed either modest or no responses in fibroblasts, respectively. This is 
interesting because the TGFB1 -1347 C and T promoter variants showed no differences in 
basal promoter activity (Figure 4.2A and B).  
 
4.7. Analysis of TGF-β1 staining in renal biopsies from HIVAN patients  
It is known from the literature that TGF-β1 is expressed in the kidney during chronic injury 
such as HIV-infection. In addition, increased TGF-β1 expression is observed during fibrosis 
and both kidney tubules and fibroblasts in the interstitium have increased TGF-β1 expression 
levels in HIV-associated nephropathy (HIVAN) renal biopsies when compared with HIV-
negative individuals (Bódi et al. 1997). In this part of the study 20 consecutive biopsies from 
a Cape Town (CPT) HIVAN sample were re-assessed in order to compare TGF-β1 staining 
to the nephrologist’s (Dr Wearne) independent histology score (Table 4.1). Table 4.1 that 
60% of the HIVAN cohort had microcysts and 90% had mild to severe fibrosis (Masson’s 
trichrome stain) on their biopsies.  
 
After optimisation of the TGF-β1 staining protocol the tubule and tubulo-interstitial (will be 
referred to as interstitium here after) staining was assessed by grading the intensity of the 
stain (1+ faint or 2+ strong) as well as the percentage of cells staining positive where 0 
indicated absence of staining, 1 indicated <10% of the cells, 2 indicated 10-30% of cells, 3 
indicated 30-50% of cells, 4 indicated >50% and 5 indicated 100% of cells staining positive. 
 
A “histo”-score or H-score was calculated for each of the biopsies where the percentage of 
cells gets multiplied by the intensity of the stain in both the tubules and interstitium for each 
tissue sample in order to compare within or between groups (McCarty et al., 1985; 
Fedchenko and Reifenrath, 2014). The grading of TGF-β1 staining was done blindly without 
knowing the severity scores for HIVAN as graded by Dr Wearne. In addition, three HIV-






Nineteen biopsies were available for the CPT-HIVAN cohort, but only 18 were analysed 
because one individual (HVN19) had too little tissue remaining and the stain could not be 
performed. All of the stains were performed on the same day with a 1:500 dilution of the 
mouse monoclonal anti-TGF-β1 antibody (see section 3.10.1. in methods and materials). 
Light microscopy images representative of the histopathological features observed in our 
CPT-HIVAN sample are shown in figure 4.7 and 4.8. The majority of the HIVAN samples 
had microcysts (tubular degeneration) and interstitial disease (inflammation and fibrosis). 
These features were not observed in the HIV-negative or –positive control tissues although 
one HIV-positive controls had some interstitial inflammation. Control biopsy kidney 
dysfunction was caused by glomerulonephritis, minimal change disease or IgA nephropathy 
(see table 4.1 and figure 4.7 e and f). 
 
No fibrosis or atrophy was observed in the control biopsy samples and the tubules and 
interstitium looked normal. All biopsies, including HIVAN and controls samples, had similar 
TGF-β1 staining of the tubular cells. The intensity of the TGF-β1 stain in the tubules was 
much stronger in the HIV-negative controls (tubular H-score=200) when compared to HIV-
positive controls (tubular H-score=100). However, 15/18 (83%) of the HIVAN samples had a 
high H-score for tubules (H-score >100) despite four samples not having microcysts.  
 
The most striking difference between HIVAN biopsies and the control biopsies (HIV+ or -) 
was seen in the TGF-β1 positive staining of the interstitium; 17/18 (94%) of the HIVAN 
samples showed TGF-β1 staining in the interstitium compared to absence in the controls. 
Comparing the interstitial TGF-β1 H-scores with the Masson’s trichrome severity of fibrosis 
grading (maximum 4) in the HIVAN samples showed that 67% (n=12 biopsies) had fibrosis 
H-scores 
 
Therefore, there was good correlation between the TGF-β1 staining pattern (% of cells and 
intensity) and the Masson’s trichrome staining. Although there are only few control biopsies 
for comparison, the most noticeable finding was the selective interstitial pathology and TGF-
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Figure 4.8: Representative light microscopy images for TGF-β1 immunohistochemical staining in 
renal biopsies from the Cape Town HIV-associated nephropathy (HIVAN) sample (n=19 
biopsies) at lower magnification (100x magnification). a and b are showing an overall view of the 
renal cortex stained with DAB (blue) to indicate the nuclei of cells and positive TGF-β1 staining 
in brown. Both a and b show the presence of microcysts, tubular atrophy, tubulointerstitium 
inflammation (white arrows) and fibrosis (black arrows). * indicating dark brown staining of 
plasma cells in the interstitium and other non-specific staining of protein deposits 
 
of ≤20 (interstitium) and mild to moderate fibrosis on the Masson’s stain (median grade 1.5, 
IQR 1; 2). The remaining 33% (n=6 biopsies) all had fibrosis H-scores >20 (interstitium) and 
these showed moderate to severe fibrosis with the Masson’s stain (median 2.5, IQR 2; 3.5) 
(Table 4.1).  
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4.8. Genotyping HIVAN sample for APOL1 and TGFB1  
APOL1 genotyping reveals 60% of HIVAN patients have one risk allele 
In order to correlate the histopathological severity of HIV-associated nephropathy (HIVAN) 
with their genotype the APOL1 gene and TGFB1 regulatory regions of 20 HIV-positive 
individuals with HIVAN and African-ancestry was sequenced. The risk alleles in the APOL1 
gene were included because of its previously reported association with increased risk of 
HIVAN in individuals with African-ancestry (Kopp et al. 2011; Freedman et al. 2014; 
Kasembeli et al. 2015).  
 
Five APOL1 haplotypes have been identified and are shown in figure 4.9. The CPT-HIVAN 
genotyping data was compared to pooled population South African controls from 
Johannesburg (HIV-negative controls, n=54 and HIV-positive control, n=54 biopsies) 
(Kasembeli et al., 2015). Importantly, in that report there was no significant difference in the 
minor allele frequencies (MAF) for APOL1 risk alleles between the HIV-positive and HIV-
negative controls (p>0.05). In addition, the CPT-HIVAN genotype data was compared with a 
HIVAN cohort previously reported from Johannesburg (JHB-HIVAN) (Kasembeli et 
al.,2015). 
 
The three APOL1 risk alleles, termed G1S342G, G1I384M and G2"6, occur at a higher frequency 
in our CPT HIVAN sample (n=40 chromosomes; MAF 0.40, 0.35 and 0.20, respectively) 
when compared to population controls (n=108 chromosomes; MAF 0.07, 0.06 and 0.11, 
respectively Figure 4.9). Genotyping results revealed that 60% of the CPT-HIVAN sample 
had ≥1 APOL1 risk allele compared to 18% in the population controls (Odds ratio [OR]=6.9, 
95% confidence interval [CI]: 3.1;15.8, p=10-6) (frequencies in figure 4.9). In addition, there 
were differences in the MAF of APOL1 risk alleles between the CPT-HIVAN and JHB-
HIVAN sample (p=0.002) (Figure 4.9 and 4.10). 
 
APOL1 risk haplotypes were also more frequent in the CPT-HIVAN sample when compared 
to the population controls, evident by the G0 haplotype (no risk) frequency of 0.40 compared 
to 0.82, respectively (Figure 4.9). The haplotype frequencies of the CPT-HIVAN group 
(frequency of 0.6 for ≥1 risk allele) were similar but slightly lower than those observed in the 
JHB-HIVAN cohort (frequency of ~0.9 for ≥1 risk allele) (p=0.002).  
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An increase in the frequency of APOL1 risk variants seemed to correlate with the presence of 
renal tubular microcysts, evident by 100% of the JHB-HIVAN group having microcysts 
compared to 60% in the CPT-HIVAN group (Table 4.1 and figure 4.10). Previously, the 
APOL1 risk allele distributions of Africans from Yoruba, Ethiopia, America and South Africa 





Figure 4.10: APOL1 risk allele distribution among different population groups. In Yoruba 
(Nigeria) 46% of the population have at least one of the G1 or G2 APOL1 risk alleles. 
African Americans have a frequency of 36% while the risk alleles do not occur in a European 
or Ethiopian population. South Africans with black African-ancestry have a frequency of 
18% in the general population, and at least 60% of those with HIVAN. The frequency of the 
APOL1 risk alleles are increased to 90% when only those individuals with microcysts are 
considered (Johannesburg).  
 
Taken together the minor allele and haplotype frequencies of APOL1 risk alleles in the CPT-
HIVAN sample differed substantially from the population controls, but were lower compared 
to the JHB-HIVAN sample. The differences between the CPT-HIVAN and JHB-HIVAN 
samples may be attributed to the stringency of histopathological diagnosis of HIVAN. 
However, it may also suggest an association between the APOL1 risk variants and the 
development of renal tubular microcysts as this was the biggest difference between the 
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criteria used (Figure 4.10). 100% of the JHB-HIVAN group had microcysts compared to 60% 
in the CPT-HIVAN group (Figure 4.10).  
 
Frequency of TGFB1 -387 C>T in HIVAN patients similar to population controls 
The TGFB1 -387 C>T variant was also genotyped for in the CPT-HIVAN sample, but due to 
technical difficulties in sequencing the TGFB1 promoter region, the other African-specific 
variants and the -1347 C>T TGFB1 ancestral variant were not included in the genotyping. 
Only 17 patients were genotyped successfully. The MAF (n=34 chromosomes, MAF=0.18) 
for the TGFB1 -387 T variant in the CPT-HIVAN sample was similar to population controls 
including both Cape Town controls (n=130 chromosomes, MAF 0.16) and Sowetan controls 
(n=188 chromosomes, MAF 0.18) (Nel et al., 2015). Of interest, two of the patients who had 
the -387 T variant were homozygous for the G1 risk variants in the APOL1 gene and were 
previously characterised as having severe HIVAN, fibrosis and microcysts (see table 4.1). 
Although only one sample, a biopsy with severe fibrosis, microcysts and significant TGF-β1 
staining in the interstitium, did not have either APOL1 risk alleles or -387 T TGFB1 variant  
(HVN18, table 4.1). 
 
In conclusion, genotyping this small sample of HIV-infected individuals who developed 
HIVAN showed that the African-specific TGFB1 –387 T regulatory variant occurred at 
similar frequencies in both the Cape Town HIVAN and South African population control 
cohorts. APOL1 risk alleles had higher frequencies in the CPT-HIVAN sample when 
compared to population controls but there were some individuals who had none of the risk 
alleles and still displayed histopathological features associated with HIVAN. 
5. Discussion 
This study focused on the functional impact of the African-specific SNPs in the TGFB1 
promoter region. Because of the high prevalence of HIV-associated kidney complications and 
specifically HIVAN in Africans, the functional effects of these SNPs were investigated in 
kidney cells. The four African-specific SNPs (-1287 G>A, -1154 C>T, -387 C>T and -14 
G>A) occur at higher frequencies in South Africans (~17%) compared to <5% in East and 
West African populations (this study and Nel et al., 2015). Haplotype analyses showed that 
the TGFB1 -1287 G>A and -1154 C>T variants are in tight linkage disequilibrium with each 
other and so are the -387 C>T and -14 G>A variants (Figure 4.1B). However, promoter-
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reporter assays showed that of the four African-specific variants, only the -387 C>T variant 
was functional in renal cells (Figure 4.2). The TGFB1 -387 C>T SNP resulted in ~5-fold 
repression of basal TGFB1 promoter activity in two renal cell lines similar to previous 
findings by Nel et al. (2015) in fibroblast and mouse myoblast cells. This repressive effect 
was also reflected at basal TGF-β1 protein level in human dermal fibroblasts with the TGFB1 
-387 T/T genotype compared to wild type -387 C/C cells.  
 
Renal and muscle cells may respond to autocrine and paracrine TGF-β1 signals in response 
to injury (Li et al. 2004; Böttinger 2007). To test this pathway renal and fibroblast cells were 
treated with recombinant human TGF-β1 (rhTGF-β1) for 1 or 6 hours. In response to this 
stimulus the TGFB1 -387 T associated repression was maintained at both the TGFB1 
promoter and TGF-β1 protein level, but interestingly not at the Smad3 level (Figure 4.3, 5.1). 
This result is similar to previous observations in transiently transfected mouse myoblasts 
which showed that treating cells with rhTGF-β1 for 6, 12 and 24 hours could not overcome 
the repressive effect observed in basal TGFB1 -387 T promoter activity (Supplementary 
figure 6.1, unpublished data from M Nel, 2014). However, activation of Smad3 after rhTGF-
β1 treatment, as measured by phosphorylated-Smad3 protein levels downstream of the TGF-
β1-dependent canonical signalling pathway (Lan 2011), was similar in dermal fibroblasts 
with either TGFB1 -387 C or T genotypes (Figure 5.1). This suggests that TGF-β1 autocrine 
signalling is normal until pSmad3 enters the nucleus, where the functional TGFB1 -387 T 
SNP results in 5-fold repression of basal promoter activity compared to the -387 C (Figure 
5.1). Previous reports have shown that the TGFB1 regulatory region contains many Sp1 (a 
transcriptional modulator) binding sites and that the -387 T SNP was predicted to alter Sp1 
binding (Nel et al. 2015). Nel et al. (2015) showed in fibroblast and muscle cells that the 
TGFB1 -387 T was less responsive to Sp1 binding when compared to the C allele (Nel et al. 
2015). This means that the loss of the Sp1 binding at the TGFB1 -387 T site is likely altering 
basal TGFB1 promoter activity and downstream TGF-β1 protein expression (Figure 5.1).  
 
This functional -387 T SNP is in tight linkage disequilibrium with another African-specific 
SNP, TGFB1 -14 G>A. Previously, using electrophoretic mobility shift assays, Shah et al. 
(2006) reported the TGFB1 -14 G>A not to affect nuclear factor binding. Nel et al. (2015) 
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performed luciferase reporter assays in fibroblast and mouse myoblast cells and found the -14 
G>A SNP not to be functional and this study confirms this finding in renal cells 
 
Figure 5.1: A model of TGF-β1 signalling in the kidney and the effect of the TGFB1 -387 
C>T polymorphism on TGFB1 promoter activity and protein expression. The schematic also 
shows the possible influence of HIV Tat on the TGFB1 promoter. TGF-β1 Smad 3 (pSmad3) 
pathway is normal for both the TGFB1 -387 C and T allele but basal TGFB1 promoter and 
protein levels are significantly lower for the T allele. The repression could be caused by the 
loss of a partial Sp1 transcription factor binding site at the -387 C>T SNP which effects 
promoter activity. Co-transfection experiments with HIV Tat protein showed that the 
repressive effect of the -387 T variant could be overcome and the exact mechanism is still 
poorly understood, however, studies have suggested that HIV Tat is able to interact with Sp1 
in order to enhance the transcription of genes. Grey arrows at the TGFB1 promoter and 
protein indicate repression/decrease in promoter activity and protein levels, respectively.  
 
Similarly, the other two African-specific SNPs, -1154 C>T and -1287 G>A, are also in tight 
linkage disequilibrium with each other (see figure 4.1B). Previous studies, using a shorter 
TGFB1 promoter construct (see figure 1.3), reported the TGFB1 -1287 A variant to be 
functional with the A allele resulting in 78% increased TGFB1 promoter activity (Shah, 
Rahaman, et al. 2006). However, using the extended TGFB1 promoter construct results 
showed that the TGFB1 -1154 C>T and TGFB1 -1287 G>A variants are not functional in two 
different renal cell lines. These differences may be the result of using an extended TGFB1 
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promoter construct in this work which contains enhancer and negative regulatory regions that 
the shorter TGFB1 promoter construct used by Shah et al. (2006) lacked. The extended 
TGFB1 promoter also contains the functional -387 C>T variant which was not included in 
the shorter TGFB1 promoter construct. 
Many studies have reported on associations with the TGFB1 -1347 C>T variant (also known 
as -509 C>T or rs1800469). The TGFB1 -1347 C>T variant has been reported to be 
functional where the T allele is referred to as the “higher expressing” variant resulting in a 
~2-fold increase in basal TGFB1 promoter activity in lung carcinoma cells, but using a 
shorter promoter construct (Shah, Rahaman, et al. 2006). This study used the extended 
TGFB1 promoter construct, which is more biologically relevant as it contains all four of the 
African-specific SNP sites. In this work, the TGFB1 -1347 C>T (or -509 C>T) was not found 
to be functional in renal cells. Previously Nel et al. (2015) using the same extended promoter 
found that the TGFB1 -1347 T (called pHap-4) resulted in 2-fold increased promoter activity 
compared with the TGFB1 -1347 C (called pHap-1) in HT1080 fibroblasts, but similar 
promoter activities in mouse myoblasts (C2C12 cells) (Table 5.1). Taken together these 
results suggest that the functionality of the TGFB1 -1347 C>T is not influenced by proximal 
promoter elements present in the extended promoter such as the African SNPs, but by trans-
regulatory factors/genes which impact its functionality in different cell types (Table 5.1).  
Table 5.1: Functional responses of the TGFB1 promoter -1347 C>T in response HIV Tat in 
different cell types.  
TGFB1 -1347 C>T (-509 C>T) 
Cell type C T 
BASAL 
Renal (RCC4+VHL and Caki-2) = = 
Fibroblast (HT1080) - ++
Mouse myoblasts (C2C12) = =
Lung (A549) - ++
HIV TAT* 
Renal (RCC4+VHL) ++ ++ 
Fibroblasts (HT1080) ++ -
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Basal refers to the basal promoter activity for the TGFB1 -1347 C or T allele observed in 
luciferase reporter assays and HIV TAT* refers to response in comparison to basal promoter 
activity after co-transfection with an HIV tat expression vector. Similar responses between 
the C and T alleles are indicated by “=”, – indicates no response compared to empty vector, 
/basal, ++ refers to ≈ 2-fold upregulation from basal. 
This study was also interested in whether the African-specific TGFB1 promoter variants had 
a potential role in HIV-associated renal complications which appear to be more frequent 
among African-Americans compared to European-Americans (Wyatt & Klotman 2009; Ray 
2012). To this end co-transfections were performed with TGFB1 promoter haplotypes and a 
HIV Tat expression vector in renal and fibroblast cell lines. Based on the basal repression 
observed with TGFB1 -387 T promoter activity, one might expect the common ancestral 
TGFB1 -1347 C haplotype (containing -387 C) to show a greater response. However, all the 
TGFB1 promoter haplotypes, with or without TGFB1 -387 T, all showed a similar increase in 
promoter activity in response to HIV Tat in renal cells. 
Previous studies have reported on the possibility that the presence of HIV Tat trans-activates 
Sp1, through the interaction with transcription co-factors, which then leads to the 
phosphorylation/activation of Sp1 in order to enhance HIV-1 viral transcription (Chun et al. 
1998; Loregian et al. 2003). Therefore, it is possible that HIV Tat may enhance Sp1 activity 
which then overcomes the repressive effect of the TGFB1 -387 T SNP. However, in 
fibroblast cells there was a differential response noted at the TGFB1 -1347 C>T (or -509 
C>T) site in response to HIV Tat (see Table 5.1). The TGFB1 haplotypes containing the -
1347 T (previously higher expressing promoter in fibroblasts) consistently did not respond to
HIV Tat in fibroblasts. The significance of these results are unclear as there are limited data
investigating the interaction between HIV Tat and the TGFB1 promoter. Previous studies,
however, have shown that the TGFB1 -1347 C>T site impacts on the binding of a
transcription factor called activator protein-1 (AP1) where the binding of this transcription
factor to the -1347 C allele decreases TGFB1 promoter activity (Shah, Hurley, et al. 2006).
Therefore, the TGFB1 -1347 C>T variant may lead to the activation of different pathways
that are phenotype specific. Previously, studies in renal biopsies focused on the effect of HIV
Tat on TGFB1 mRNA and protein expression rather than the mechanism whereby the
observed upregulation occurs. Taken together, these results suggest that HIV Tat influences
the functionality of the TGFB1 -1347 C>T (or -509 C>T) variant in fibroblasts cells.
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The mechanism of HIVAN pathogenesis is still not fully understood (Ross et al. 2001; 
Medapalli et al. 2011) and this study had the opportunity to assess TGF-β1 staining in a small 
sample of renal biopsies from HIV-positive patients with renal dysfunction. These 
individuals were about to start antiretroviral therapy and their TGF-β1 staining patterns were 
compared to renal biopsies from HIV-negative and HIV-positive control biopsies without 
HIVAN. The most striking finding was that the HIVAN biopsies showed specific TGF-β1 
staining of the renal interstitium in contrast to the biopsies from HIV-positive and -negative 
controls despite similar intensity and percentage of tubular epithelial cells staining positive 
for TGF-β1 to control biopsies. However, this result must be interpreted with caution as it 
was a small sample and the result differs from previous studies where increased TGF-β1 
staining in the interstitium was observed for HIV-positive biopsies even without HIVAN 
compared with HIV-negative biopsies (Bódi et al. 1997; Yamamoto et al. 1999). Future 
studies will have to investigate TGF-β1 staining in a larger sample, particularly for HIV-
positive non-HIVAN controls.  
 
DNA samples from the individuals who had been biopsied for TGF-β1 staining were 
genotyped for the TGFB1 promoter variants as well as the previously identified APOL1 
HIVAN risk variants. Unfortunately, due to technical difficulties only the TGFB1 -387 C>T 
genotyping was completed in 17 of 20 individuals. Although a small sample, the genotype 
frequencies at this locus in the HIVAN group was identical to population controls arguing 
against an association with the functional African-specific TGFB1 -387 C>T SNP. The 
APOL1 genotyping confirmed the previous observations of Kasembeli et al. (2015) that the 
≥1 APOL1 risk alleles occurred at a higher frequency in the South Africans with HIVAN 
compared to population controls (Figure 4.9). There is also a difference observed for APOL1 
risk alleles frequencies between the Johannesburg HIVAN (Kasembeli et al., 2015) and the 
Cape Town HIVAN samples (p=0.002) raising the question of HIVAN classification criteria 
used by the two studies. There is a general agreement about the histopathological features of 
HIVAN in the literature, but exact defining histopathological characteristics appear to be less 
agreed upon. For example, in this study only 8/20 individuals from HIVAN group had 
microcysts while all (n=76 individuals) of the individuals in the Johannesburg HIVAN 
sample had microcysts (Kasembeli et al. 2015) (Figure 5.2). In addition it may suggest that 
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APOL1 variants increases the susceptibility of developing renal tubular microcysts in 
HIVAN. APOL1 risk alleles are not present in Europeans, likely due to positive evolutionary 
pressure in areas such as West Africa which resulted in the influence of APOL1 variants in 
order to infer resistance to trypanosomal parasites specific to the area (Genovese et al. 2010). 
The frequency of APOL1 risk alleles in African Americans is 46% because their genetic 
ancestry is likely more than 80% African. Interestingly, the frequency of the risk alleles in 
Ethiopians is ~0% and in South African black controls 18% (Figure 4.10).  
 
Bioinformatics analysis through SIFT and PolyPhen-2 software (available on Ensemble, 
http://www.ensembl.org/Multi/Search/Results?q=rs73885319;site=ensembl) shows that the 
two G1 risk alleles are missense variants that are benign while the effect of the 6bp deletion 
G2 risk allele is still unknown. Nichols et al. (2015) has shown that the regulation of APOL1 
may be through antiviral pathways, such as the Toll-like receptor 3 pathway (Nichols et al. 
2015), but studies investigating APOL1 regulation is still limited and needs to be further 
explored. One study has shown that APOL1 staining in renal tubular epithelial cells is lower 
in HIVAN biopsies compared to normal kidneys (Madhavan et al. 2011). However, Although 
APOL1 risk alleles co-occur with a variety of different kidney diseases (Larsen et al. 2015) it 
would also be interesting to assess whether it associates with a particular histopathological 
pattern. Such genotype-phenotype correlation may give more insight into the pathogenesis of 
HIVAN.  
 
Previous studies have shown that APOL1 is regulated by cytokines released during the innate 
immune response which includes the interferon-gamma(#) (IFN-#) and tumour necrosis 
factor (TNF) pathways and influences the inflammatory response and APOL1 expression in 
renal tubular epithelial cells and podocytes (Sana et al. 2005; Nichols et al. 2015). Figure 5.3 
shows a STRING map of potential protein-protein interactions for APOL-1 which is 
generated using STRING version 10.0 software (http://string-
db.org/cgi/network.pl?taskId=hJgCmFgJagM7) based on prediction software data from other 
databases and published data in the literature (Szklarczyk et al. 2015). Interestingly, the Sp1 
transcription factor was identified as a possible protein interacting with APOL1 and may be a 

















Figure 5.2: STRING map showing potential protein-protein interactions for APOL1. As 
indicated in the key blue and pink lines indicate known interactions between proteins with 
evidence acquired form curated databases and experimental data. The green lines indicate 
potential protein-protein interactions between those proteins often mentioned together in the 
literature. Protein-protein interaction scores are also shown and all fall in the medium-to-high 
confidence range which is calculated based on experimental data of each interaction taking 
into account sequence, structure and functionality (Szklarczyk et al. 2015). The protein-
protein interaction score for the Sp1 transcription factor is of high confidence (0.664).  
 
Limitations and future studies 
This study has several limitations. The sample size for Cape Town HIVAN biopsies was too 
small for any significant conclusions based on TGF-β1 staining patterns or TGFB1 
genotyping. Also, the TGFB1 -1347 C>T variant was not included in the genotyping of the 
HIVAN samples and may be informative in future studies. 
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This study did not explore the possible transcription factor binding sites (TFBS) that may be 
influenced by the TGFB1 -1347 C>T variant, such as AP1. Das and Sharma (2014) discuss 
the importance of investigating the genetic factors modulating susceptibility of complex 
diseases and their manifestations. For example, the expression of a gene/protein can be 
influenced by cis promoter variants such as the TGFB1 -1347 C>T and trans promoter 
variants that are further away (more than 500kb away) from the transcription start site or on a 
different chromosome. It has also been shown that trans variants are able to effect tissues 
specific expression of genes (Das & Sharma 2014; Bryois et al. 2014), therefore, in the 
context of the TGFB1 -1347 C>T variant and HIV, there seems to be a trans-variant/gene 
effect causing differential expression in several different cell types that needs to be 
investigated further. HIV infection of renal cells can also effect epigenetic changes in gene 
regulation which, in the context of HIVAN, might be a master regulator of the TGF-β1 
pathway.  
This study only interrogated TGF-β1 and phosphor-Smad3 protein levels as an indication of  
the TGF-β1 autocrine pathway, but as mentioned earlier in section 1.2 and 1.3 there are many 
other factors involved in the regulation of TGF-β1 signalling in the kidney. Future studies 
may investigate TGF-β1 signalling inhibitors and TGF-β1-independent pathways in order to 
fully characterize the TGF-β1 pathway in HIVAN individuals with African-ancestry.  
The possible interaction between HIV Tat and the transcriptional activator Sp1 was not 
investigated in this study, neither was the effect of the TGFB1 -387 C>T variant on Sp1 
binding in the context of renal cells. Future studies may want to investigate whether the same 
Sp1 sensitivity at the TGFB1 -387 C>T site is observed in renal cells. Previous studies have 
analysed TGF-β1 protein levels by treating cells with human recombinant HIV Tat protein 
which is a more biologically relevant way to investigate its effect (Lotz et al. 1994; 
Yamamoto et al. 1999). This study used a HIV Tat expression vector in order to 
overexpressed HIV Tat intracellularly and therefore the results may be different when using 
extracellular HIV Tat stimulation. Due to the fact that HIV-infection occurs in the renal 
tubular epithelial cells and because HIV Tat and Nef proteins have been shown to act 
together to enhance viral transcription in kidneys using a mouse model (Joseph et al. 2003; 
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Dickie et al. 2004), one might speculate that these two proteins act together in a HIVAN 
context. Future studies might want to investigate whether the addition of other HIV genes 
have an effect on TGFB1 promoter activity using in vitro experiments with renal cells where 
expression vectors contain tat, nef and vpr genes. (Dickie et al. 2004; Zuo 2006; Rosenstiel et 
al. 2009). 
 
The HIVAN biopsies used in this study to interrogate TGF-β1 staining patterns were taken 
before the patients were given antiretroviral therapy (ART). Previous reports have shown that 
ATR leads to decreased fibrosis in HIVAN biopsies and it has been suggested that ART and 
steroids are used in the treatment of HIVAN (Weiner et al. 2003; Kalayjian 2011; Wearne et 
al. 2012). In the context of this study it will be of interest to investigate whether the TGF-β1 
staining in the interstitium decreases after ART and compare the staining patterns with renal 
histopathology/outcomes.  
 
As previously mentioned in section 1.3, changes in APOL1 expression can disrupt renal 
epithelial cell homeostasis and autophagy. Although this study showed that the APOL1 risk 
alleles have a strong correlation with the presence of microcysts in the HIVAN biopsies, the 
mechanism whereby this is happening was not investigated and needs further exploration.  
 
Future studies may also want to investigate whether there are differences in APOL1 protein 
expression between the Cape Town HIVAN biopsies and HIV-negative and –positive 
controls. The exact mechanisms for APOL1 regulation is still poorly understood and further 
exploration into which pathways are responsible will benefit our understanding of the role 
APOL1 plays in the pathogenesis of HIVAN.  
 
Conclusion 
In conclusion this study has shown that there is no difference in TGFB1 promoter activity 
between the -1347 C and T alleles in two renal cell lines and suggests that the functionality of 
this SNP may be cell type specific. This study also shows that the African-specific TGFB1 -
387 C>T variant is functional and results in repression of basal promoter activity and lowered 
TGF-β1 protein levels when compared to dermal fibroblasts with the -387 C allele. The TGF-
β1-Smad3 pathway was normal in all cells, despite having the TGFB1 -387 T SNP, and 
exogenous treatment with TGF-β1 did not overcome the repressive effect of the -387 C>T 
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variant on TGFB1 promoter activity. This suggests that the pSmad3 complex is unable to 
activate the TGFB1 promoter once inside the nucleus, which may be due to the -387 C>T 
resulting in the loss of a transcription factor binding site. This work also confirms that HIV 
Tat upregulates TGF-β1 protein levels in renal cells, but shows that the TGFB1 -1347 T allele 
is unresponsive compared to cells with the -1347 C allele in fibroblast cells. This study is also 
one of few that suggests the possible influence of APOL1 risk alleles on the formation of 
microcysts in renal tubular cells. Taken together this study highlights the complexity of 
HIVAN pathogenesis and TGF-β1 signalling in the kidney and suggests that susceptibility is 
influenced by more than one risk variant which influences the regulation of many different 
pathways. These risk variants together with environmental factors, such as HIV-infection, 
contribute to molecular phenotypes which ultimately result in the formation of glomerular, 
















Figure 5.3: Proposed model of biological factors influencing HIVAN. HIV-infection together 
with risk variants, such as the APOL1 HIVAN risk alleles and other unidentified variants, 
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leads to altered gene regulation and altered TGF-β1 signalling in renal tubular epithelial cells 
and fibroblasts in the renal interstitium. This dysregulation can increase the susceptibility to 
developing HIVAN and lead to a constellation of glomerular, interstitial and tubular 
abnormalities in the kidney. The APOL1 risk variants also seem to be driving the formation 
of renal tubular microcysts during HIVAN. Figure adapted from Das and Sharma (2014). 
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6. Supplementary figures 
 
 
Supplementary figure 6.1: Human recombinant TGF-β1 does not consistently activate the TGFB1 
promoters in mouse myoblast cells. C2C12 (mouse myoblasts) were transiently transfected for 30 
hours with H-ANC and H-AFR TGFB1 promoter haplotypes and serum starved 16 hours prior to 
harvesting. The cells were treated with 5µg/ml human recombinant TGF-β1 (hrTGF-β1) for 6, 12 
and 24 hours before harvesting. Luciferase activity was measured 30 hours following transient 
transfection and expressed as the ratio of firefly to renilla luciferase activity for each of the 
haplotypes. pRL renilla reporter was used to control for transfection efficiency. These are pooled 
results of ≥2 independent experiments (except 12-hour treatments for both promoters), each 
performed in duplicate. Statistical differences (including trends) are shown in the figure. 
Student’s paired t-test, two-tailed, was performed for treated versus untreated for each of the 
haplotypes, error bars standard error of the mean (SEM). Student's unpaired t-test, two-tailed, was 
performed to compare the H-ANC and H-AFR TGFB1 haplotypes, two-tailed, error bars SEM. 
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Supplementary figure 6.2: Flow-chart with summary of techniques and results for this study. Aim 
1 was to determine whether the African-specific TGFB1 regulatory/promoter variants were 
functional. To this end haploview analysis was performed on n=344 chromosomes from 
population controls and six biologically relevant haplotypes were identified and generated via 
site-directed mutagenesis. The TGFB1 promoters were then transiently transfected into two renal 
cell lines (RCC4+VHL and Caki-2) and promoter activity was measured in order to compare 
functionality of the African-specific variants. The effect of the African-specific variants on TGF-
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β1 autocrine stimulation was also investigated at TGFB1 promoter level (with recombinant 
human TGF-β1) before investigating their effect on TGF-β1 and pSmad3 protein levels (as an 
indicator of downstream TGF-β1 canonical pathway). TGF-β1 and pSmad3 protein levels were 
also measured after stimulation with recombinant TGF-β1 in order to investigate whether the 
effects seen at TGFB1 promoter activity is maintained at the protein level. The effect of HIV tat 
protein on the TGFB1 promoters and whether the TGFB1 -387 T affects the activation/repression 
was also investigated. Aim 2 focused on the potential role/effect of the African TGFB1 promoter 
variants in HIV-associated kidney complications. To this end n=20 biopsies form patients with 
HIV-associated nephropathy (HIVAN) were analysed for TGF-β1 staining patterns and compared 
to those of HIV-positive and –negative control biopsies without HIVAN. The genomic DNA 
from the n=20 HIVAN patients were also genotyped for the TGFB1 -387 C>T and APOL1 risk 
alleles and compared to previously genotyped population control groups from South Africa.  
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Competent cells, site-directed mutagenesis, mini preparation and maxi preparation of DNA
50% Glycerol 
To make 100ml: 
Take 50ml of 100% glycerol and dilute it with 50ml ddH2O 
100 mM CaCl2 
1.4702g CaCl2 
Dissolve in 90ml double distilled water (ddH2O) 
Make up to 100ml 
Autoclave before use 
Store at room temperature 
Luria Broth (LB) 
Makes 1L 
10g Bacto-tryptone  
5g Bacto-yeast extract  
10g Sodium Chloride (NaCl) 
Dissolve in 900ml ddH2O  
Make up to 1L with ddH2O 
Autoclave before use 
LB Agar  
3g OXOID Agar Bacteriological to 200ml LB 
Autoclave before making Ampicillin plates 
LB Ampicillin plates 
Add 100µg/ml Ampicillin to the LB agar and pour the solution into bacterial plates 
(±20ml/plate) and leave to set at room temperature (RT).  
Makes ±10 plates 
1% Agarose gel 
Makes 50ml 
0.5g Agarose  
50ml Tris/Borate/EDTA (TBE) 
1µl Ethidium Bromide (EthBr) 
Dissolve agarose/Tris solution in microwave and allow to cool before adding the EthBr. Pour 






55g Boric acid  
40 ml 0.5M Disodium EDTA (pH 8.0) 
 
1X TBE 
100ml 10X TBE 






13.5g Dulbecco’s Modified Eagle’s medium powder  
3.7g Sodium Hydrogen Carbonate  
Dissolve in 700ml and bring up to 1L 
Adjust pH to 7.2 – 7.4 








20mM Citric Acid 
55mM Disodium hydrogen phosphate dehydrate 
50% Glycerol 
Adjust to pH 5.5 
Store at 4°C 
 
β-galactosidase stain 
5mM Potassium ferrocyanide 
5mM Potassium ferricyanide 
2mM Magnesium chloride 
1mg/ml X-gal (in DMSO) 
 
Protein harvest and western blot analysis 
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5X protein dye 
50% Glycerol 
5% Sodium-dodecyl sulphate (SDS) 
0.25M Tris-Cl pH 6.8 




10% resolving gel: 
40% Acrylamide 





5% stacking gel: 
40% Acrylamide 
1.5M Tris pH 6.8 
10% SDS 





0.1g APS  
Make solution up to 1ml using dH2O 





Make up to 1L with dH2O and adjust to pH 7.2 
Store at RT 
 
10X Running buffer 
144g Glycerine 
30g TRIS powder 
10g SDS 
Make up to 1L with dH2O 
 
1X Running buffer 
100ml of 10X Running buffer 
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Make up to 1L with dH2O 
10X Transfer buffer 
144g Glycerine 
38g TRIS powder 
Make up to 1L with dH2O 
1X Transfer buffer 
100ml of 10X Transfer buffer 
200ml Methanol 
Make up to 1L with dH2O 
Phosphate-buffered Saline (PBS) (10x) 
Makes 1L 
80g NaCl 
26.8g Sodium Dihydrogen Phosphate Dodecahydrate 
2g Potassium chloride 
2.4g Monopatassium phosphate 
Make up to 1L using dH2O before adjusting to pH 6.9 
Autoclave before use 
For 1X PBS (1L): 100ml 10xPBS with 900ml dH2O 





Make up to 1L using dH2O before adjusting to pH 6.9 
Autoclave before use 
For 1X TBS (1L): 100ml 10xTBS with 900ml dH2O 
TBS/TWEEN 
Makes 500ml 
500ml 1X TBS 
500µl Tween 20 
PBS/TWEEN 
Makes 500ml  
500ml 1X PBS 




5% Milk in PBS/Tween: 
Makes 50ml 
2.5g Milk powder 
Make up t0 50ml with PBS/Tween 
Phospho-Smad3 antibody: 
5% Milk in TBS/Tween: 
Makes 50ml 
2.5g Milk powder 
Make up t0 50ml with TBS/Tween 
TGF-β1 antibody: 
5% Bovine Serum Albumin (BSA) in TBS/Tween 
2.5g BSA powder 
Make up to 50ml with TBS/Tween 
Radioimmunopercipitation assay (RIPA) buffer 
150mM NaCl 
1% Triton 100X 
0.1% SDS 
10mM Tris pH 7.5 
1% Deoxycholate 





Dissolve and make up to 2L with dH2O before adjusting to pH 9.0 
